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ABSTRACT
Human Herpesvirus 6A (HHV-6A) and 6B (HHV-6B) are ubiquitous
betaherpesviruses. Both viruses are associated with a variety of adult disorders
including neurological disorder, such as multiple sclerosis and chronic fatigue
syndrome. HHV-6 viruses are capable of establishing latency by integration into the
telomeres of the host chromosome and are transmitted in a Mendelian manner in
approximately one percent of the population. To date little is known about the
immunological and neurological consequences of HHV-6 inheritance. This study
focused on a unique population of individuals that inherited HHV-6 and present with
chronic fatigue-like symptoms, including hypersomnia, generalized fatigue, headache,
and short term and long term memory impairment. The central hypothesis of this study
was that active replication of HHV-6 correlates with patient symptoms. To address this
aim we first looked at the reactivation of integrated HHV-6 in vitro by inducing viral
replication with epigenetic modifiers trichostatin A (TSA), valproic acid, sodium butyrate,
and carbamazepine, and found TSA to be an effective method of inducing reactivation
of HHV-6 from its integrated form. Additionally, a reactivated HHV-6A virus isolated from
a patient with inherited HHV-6 was fully sequenced and the nucleotide and amino acid
sequence was compared to that of fully sequenced HHV-6 laboratory strains, as well as
the inherited virus. The reactivated virus was found to be very similar to the HHV-6A GS
strain; however, there was some divergence at the right end of the viral genome and
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regions of the genome that do not contain herpesvirus core genes. Interestingly, the
sequenced reactivated virus was found to differ from the HHV-6 virus which was
inherited. Finally, HHV-6 replication was assessed by performing reverse transcriptase
PCR assay for the viral glycoprotein U100 in patients receiving antiviral treatment.
Results indicated that short term antiviral treatment was insufficient to abrogate viral
replication, while treatment of six weeks or longer eliminated viral mRNA in patient
blood samples. Furthermore, sequencing of the viral mRNA and inherited viral DNA
indicate that the source of the mRNA detected in patient blood samples was an
exogenously acquired HHV-6 virus, as the U100 glycoprotein sequences were not
identical. Together these studies indicate that although HHV-6 can be reactivated from
its integrated form, individuals in this unique population harbored an exogenous HHV-6
virus, in addition to the inherited virus; we termed this condition inherited herpesvirus
syndrome. The fact that these individuals are able to acquire exogenous HHV-6 viruses
suggest that there may be some level of immune tolerance or immune dysfunction; we
suggest that further studies focus on uncovering the immune response to HHV-6 in
individuals with an inherited form of the virus.
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INTRODUCTION

Herpesviridae Structure
The Herpesviridae family of viruses is comprised of greater than 200
herpesviruses that infect mammals, birds, and reptiles. Irrespective of the natural host,
all herpesvirus virions range in size from 120-260nm and have a similar structure (1). At
the core of the virus particle, is the double stranded DNA genome that is tightly
packaged into an icosahedral nucleocapsid comprised of 161 hexameric and
pentameric capsomeres. Surrounding and tightly associated with the nucleocapsid is an
amorphous, fibrous structure made of a compilation of viral and cellular proteins known
as the tegument. Viral tegument proteins are important for propagating infection and
often interfere with the host innate response to the virus. Examples of tegument proteins
include HSV UL41 protein that targets cellular mRNA for degradation, and US3 that
inhibits toll like receptor 2 (2,3). The most outer layer of the virion is a lipid bilayer
envelope with glycoprotein protrusions. Glycoproteins often serve as ligands for cellular
receptors or some are essential for cell fusion (1,4).
Classification of Human Herpesviruses
The nine human herpesviruses may be classified into three subfamilies and six
genera based on DNA sequence, similarity of encoded proteins, site of latency, and
other biological properties (Table 1). The human members of the Alphaherpesvirinae
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subfamily include herpes simplex viruses 1 & 2, as well as Varicella-zoster virus; the
Alphaherpesviruses infect and establish latency in sensory ganglia. Cytomegalovirus
(CMV), human herpesvirus 6A, 6B, and 7, are members of the Betaherpesvirinae
subfamily. CMV establishes latency in monocytic cells and the bone marrow; however,
there is no conclusive evidence indicating the natural site of latency for the HHV-6
viruses or for HHV-7. The viruses belonging to the Gammaherpesvirinae subfamily are
known for their oncogenic potential; gammaherpesviruses establish latency in lymphoid
cells. The two human gammaherpesviruses, Epstein-Barr virus and Kaposi’s sarcomaassociated herpesvirus, both establish latency in B-lymphocytes.

Figure 1: The Structure of Herpesviruses. Each herpesvirus particle is comprised of
a double stranded DNA genome contained within a capsid, tegument, and envelope.
Protruding from the surface of the envelope are glycoproteins (1).

Genome Organization of Human Herpesviruses
The genomes of the human herpesviruses range in size from 145 to 230 kbp (1).
Despite some conservation in the encoded genes, the genomic arrangement varies
from one virus to another (Figure 2). The majority of the genome length is attributed to
2

the unique length region, which contains the majority of the protein-coding genes (1).
The unique length segment may occur as a single unit or may be separated via one or
more blocks of intervening repeated sequences, creating a unique long or two or more
unique short regions (1).

Table 1: Classification of Human Herpesviruses (1)
Designation

Common Name /Abbreviation

Subfamily

Genus

HHV-1

Herpes simplex virus 1 (HSV-1)

Alpha

Simplexvirus

HHV-2

Herpes simplex virus 2 (HSV-2)

Alpha

Simplexvirus

HHV-3

Varicella-zoster virus (VZV)

Alpha

Varicellovirus

HHV-4

Epstein Barr virus (EBV)

Gamma

Lymphocryptovirus

HHV-5

Cytomegalovirus(CMV)

Beta

Cytomegalovirus

HHV-6A

Human herpesvirus 6A (HHV-6A)

Beta

Roseolovirus

HHV-6B

Human herpesvirus 6B (HHV-6B)

Beta

Roseolovirus

HHV-7

Human herpesvirus 7 (HHV-7)

Beta

Roseolovirus

HHV-8

Kaposi’s sarcoma-associated
herpesvirus (KSHV)

Gamma

Rhadinovirus

Additionally, the genomes of the human herpesviruses characteristically contain
a variable number of repetitive elements at the ends and/or within the genome. When
internal repeats are inversions of terminal or internal reiterations (inverted repeats),
isomers may arise due to recombination of complementary sequences during viral
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replication (1). Of the human herpesviruses, only HSV-1, HSV-2, VZV, and CMV have
inverted repeats(1).
The genome of HHV-6A and HHV-6B are 159kbp and 162kbp, respectively. An
8-13kb segment, designated direct repeat left (DRL) or right (DRR)(5–7), is duplicated in
the same orientation at both ends of the unique length. At the outer regions of the direct
repeat are a variable number of telomere repeats that are either perfectly reiterated
(perfect repeats) or repeated with other interspersed hexameric sequences (imperfect
repeats) (7). The telomere repeats of HHV-6 are identical to that of the human telomere
repeats and the perfect repeats at the right end of the viral genome are in the same
orientation of the human telomeres, facilitating recombination between viral and host
repeats. In addition to the telomere repeats, the genomes of HHV-6A and HHV-6B have
major repetitive elements located at near the right end of the unique length region: R1,
R2 , and R3; HHV-6B has an additional repetitive element R0 located at the junction of
the DRL and the unique segment (1,5,6).
Herpesvirus Replication: Lytic Replication, Latency, and Reactivation
Three replication properties shared by all herpesviruses are (1) replication of the
viral DNA within the nucleus (2) a replication cycle includes primary infection, and a
period of lytic replication during which new virus production occurs or the establishment
of latency, and (3) after a variable period of latency, reactivation may occur, leading to
the production of infectious viruses.
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IRL IRS
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HSV-1
HSV-2

IRL IRS
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CMV
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R1R2 R3
U
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U2 R2
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KSHV

U3

R3

U4

R4

U5

TR

TR

LUR

Figure 2. The Genome Organization of Human Herpesviruses. Solid lines represent
the unique length (U) regions of the genome: The unique (U), unique Long (UL), unique
short (US), and long unique regions (LUR) are represented by solid lines. Box regions
represent repetitive elements of the genome: TR (terminal repeats), TRL (long terminal
repeat), or TRS (short terminal repeat). For HHV-6A, 6B, and 7 the direct repeats (DRL
or DRR), the black boxes represent the perfect telomere repeats, while the gray boxes
represent the imperfect telomere repeats (1,5,8,9).

Lytic Replication
Infection of herpesviruses begins with receptor binding, fusion of the viral and
cellular membrane, and the release of the viral genome into the nucleus of the cell (1).
Prior to the start of lytic replication, the DNA genome of the virus circularizes, and viral
gene products are synthesized in a lytic cascade. At the earliest time points of infection,
5

tegument proteins are expressed. Next, the immediate early (IE) genes that function as
transcriptional regulators are expressed. IE gene expression occurs independent of
protein synthesis, and is therefore produced in the presence of cycloheximide in vitro.
Next, the early genes, which are expressed independently of viral DNA synthesis, are
synthesized; these genes encode proteins such as the viral primase/helicase, and DNA
polymerase, which are required for viral DNA replication. In the final phase of the lytic
cascade, the late genes that encode structural proteins for new virion production, such
as capsid proteins and glycoproteins, are synthesized.
During DNA replication, the circularized viral genome is duplicated by a rollingcircle mechanism (10,11). At the start of replication, a short RNA primer is made by the
viral primase. Replication begins at an origin of replication and proceeds around the
circle, resulting in the formation of catenated genomes. For new viral particles to be
made, cleavage of the concatemers must occur and single length genomes need to be
packaged into empty nucleocapsids. During lytic replication, the production and release
of new viral particles results in the lysis of the host cell.
Latent Infection
As an alternate to lytic replication, herpesvirus may enter a period of latent
infection following infection of new target cell cells (1). In contrast to lytic replication,
gene expression is highly restricted during latency. Genes that are essential for the
production of new viruses are repressed, and only genes required for maintenance of
the viral genome and latency associated genes are expressed. In most cases, during
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herpesvirus latency, multiple circularized copies of the viral genome found within the
nucleus are tethered to the chromosome.
Latency of HHV-6
HHV-6A infects cells via the CD46 receptor, while HHV-6B infects cells via the
CD134 receptor (12,13). It has been suggested that the natural site of latency for HHV-6
viruses is the monocyte/macrophage cell population (14). Additionally, there is in vitro
evidence of establishment of latency in other cell types including astrocytes, Tlymphocytes (15,16). There is no conclusive evidence on the natural site of latency
during HHV-6 infection.
In contrast to other human herpesviruses, HHV-6 viruses do not form circular
episomes during latency. Initial reports of HHV-6 latency in patient PBMCs indicated a
covalent linkage between HHV-6 DNA and high molecular weight cellular DNA (17).
However, the mechanism of latency and the orientation of the genome during latency
were not elucidated for another decade. More recently, Arbuckle et al. demonstrated
that latency of HHV-6 viruses occurs by homologous recombination between telomerelike repeats at the telomeres at the end of the host chromosomes (15). This method of
integration was observed in vitro as well as in patient PBMC samples (15). Southern
blot hybridization and cloning and sequencing of the integration site, showed that during
integration, the HHV-6 genome is oriented so that the perfect telomere repeats at the
right end of the viral genome is adjacent to the subtelomere of the human chromosome
(15). Additional experiments also demonstrate that during integration both direct repeats
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are present and the imperfect telomere repeats at the left end of the viral genome
adjoins the telomere of the host chromosome (18). (Figure 3)

Figure 3: The Model of HHV-6 Integration. During homologous recombination the
presence of perfect telomere repeats (black box) and imperfect telomere repeats (grey
box) at the end of the direct repeats allow integration into the host telomeres via
homologous recombination (18).

Reactivation
Herpesvirus latency is not abortive; the quiescent virus may produce infectious
virus particles at a later point. A variety of factors may lead to the reactivation of
herpesviruses in their natural hosts, such as immune suppression, UV exposure, and in
some cases hypoxia (19,20). In tissue culture models, some latent herpesviruses are
inducible by chemical compounds which serve as epigenetic modulators which alter
chromatin structure or mediate RNA polymerase to access DNA. To name a few, DNA
methyltransferase inhibitor, 5-azacytidine, and HDAC inhibitors, trichostatin A (TSA) and
sodium butyrate, are all capable of inducing viral gene transcription (21–25).
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HHV-6 History
In 1986, HHV-6 was first isolated from the PBMCs of six immunodeficient
individuals who presented with a variety of lymphoproliferative disorders, including
HTLV, B-cell lymphoma, and acute lymphocytic leukemia (26). Preliminary reports
identified the virus as a novel herpesvirus that primarily infects B-lymphocytes;
therefore, the virus was designated human B-lymphotropic virus or HBLV (26). Shortly
after initial identification, studies demonstrated that in culture HBLV/HHV-6 selectively
infects and efficiently replicates in T-lymphocytes with a preference towards CD4+ Tcells (27–29). Although HHV-6 viruses are primarily lymphotropic, additional sites of
replication for the viruses include monocytes/macrophages, and astrocytes (14,16).
HHV-6 Transmission
After primary infection, HHV-6 is detectable in saliva, nasal cavity, cervix and
female genital tract (30–32). The main route of HHV-6 transmission is oral transmission
via saliva; most children are infected by the age of two (33).
Additionally, HHV-6 viruses may be transmitted congenitally by one of two
mechanisms: transplacental/perinatal infection or inheritance (15,34–38). Integration of
HHV-6 in the telomeres of germline cells, a condition known as chromosomally
integrated HHV-6 (CIHHV-6), results in vertical transmission of the virus in a Mendelian
manner. All CIHHV-6 positive individuals harbor one copy of the viral genome in every
nucleated cell; there has been a single report of an individual who inherited one copy of
the viral genome from each parent (37). Over the past twenty years, several
independent groups reported HHV-6 integration/inheritance; evidence was primarily
9

obtained by fluorescent in situ hybridization studies to determine integration site (38–
41). More recently, Arbuckle et al. cloned and sequenced the integration site, while also
performing partial sequence analysis to confirm that the integrated virus is the same in
all CIHHV-6 family members (15). The rate of inheritance in the general population is
approximately 1% in the United States and the United Kingdom, with an increased
prevalence seen in hospitalized patients (40,42–49). To date eight unique HHV-6 sites
of integration have been reported in the literature: 1q, 9q, 10q, 11p, 17p, 18q, 19q, 22q
(15,17,37–39,50–53). Congenital HHV-6 infection may also result from intrauterine or
transplacental infection. HHV-6 has successfully been detected in cervical swabs of
pregnant women (30,54), as well as in placenta samples obtain during birth (55), and
recent reports confirm that transplacentally acquired HHV-6 may occur due to
reactivation of a maternal chromosomally integrated HHV-6 (CIHHV-6) strain (30,36).
Although inheritance of HHV-6 is relatively low in the general healthy population, it is
considered the major mode of congenital infection (34).
Transplant related HHV-6 transmission may also occur by either donor
transmission or reactivation of the virus. Transmission of integrated HHV-6 via
transplant has been noted in hematopoietic stem cell recipients, as well as liver, kidney,
and small bowel transplant patients (40,45,46,56). The implications of CIHHV-6
transmission is not fully understood; however, a common problem is misdiagnosis of
active replication and treatment with antivirals in the absence of HHV-6 related clinical
symptoms (41,51,57,58). Additionally, transmission via solid organ transplantation
resulting in antibody responses characteristic of primary HHV-6 infection has been
documented (59).
10

HHV-6 Epidemiology
Prevalence
Seroprevalence of HHV-6 ranges up to 100% in most regions of the world (60).
However, there is a disproportionate number of childhood infections with HHV-6B in the
United States, Japan, and some regions of Europe, rather than HHV-6A (61,62). In
these regions, infections with HHV-6A are generally seen in adult populations who are
experiencing immunological or neurological disorders. An exception to this trend is seen
in regions of Sub-Saharan Africa, where the prevalence of HHV-6A is as high as 85% in
healthy children (63).
The rate of inheritance of HHV-6 is approximately 1% in the United States and
the United Kingdom. However, and increased prevalence has been noted in some
populations of transplant patients and pediatric encephalitis patients (34,42,46,56,64–
67). Inheritance of both HHV-6A and HHV-6B occurs. However, there are insufficient
data at this time to determine which variant is most commonly inherited.
HHV-6 Disease Associations and Complications
Exanthema subitum
In most regions of the world, primary HHV-6B infection occurs by the age of two
and the virus is considered ubiquitous in the healthy population (1,68). HHV-6B is one
of the causes of exanthema subitum, also known as roseola infantum or sixth disease
(69). Exanthema subitum is characterized by a sudden onset fever, followed by a rash
on the trunk, extremities, and face. Although rare, complications associated with
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exanthema subitum include convulsions and encephalitis (1). Primary infection with
HHV-6 in adults is rare, but may result in a mononucleosis-like disease (70).
AIDS Progression
While HHV-6A has not conclusively been implicated as the etiological agent for
any diseases, it may play a role in AIDS progression. HHV-6 viruses predominantly
replicate in CD4+ T-cells, the target cells of the HIV virus. In vitro, HIV and HHV-6 can
together productively infect CD4+ T cells, and dual infection has been noted in infants
and adult (62,63). HHV-6 infection leads to trans-activation of HIV LTR and increased
HIV gene expression (71,72). Furthermore, in a pig-tail macaque model, animals
infected with both HHV-6A and simian immunodeficiency virus (SIV) progression to
AIDS and depletion of CD4+ and CD8+ cells occurred faster than in animals infected
SIV alone.(73). Accelerated progression to AIDS was also noted when animals were
infected with HHV-6 prior to SIV infection.
Multiple Sclerosis
The cellular receptor for HHV-6A viruses is the ubiquitously expressed CD46
receptor; in contrast, CD134 is used by HHV-6B viruses for infection. In vitro studies
have demonstrated experimental infection of a variety of cell types including neuronal
cells (12,16,74) with both viruses. The nasal cavity is a reservoir for HHV-6 viruses; and
from there HHV-6 gains access to the central nervous system via the olfactory pathway
(31). Both HHV-6A and HHV-6B are able to infect cells of neuronal origin. However,
only HHV-6A is able to establish productive infection in astrocytes and
oligodendrocytes; HHV-6B infection in these cell types is abortive (16,31,74,75).
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It has been suggested that HHV-6 plays a role in the progression of multiple
sclerosis (MS); however, this relationship remains controversial. Staining of neurons
and oligodendrocytes on brain specimens in the United States detected using
antibodies against HHV-6 virion protein and DNA binding protein in both control and MS
brains. However, HHV-6 antigen detection in oligodendrocyte and neuronal plaques
was significantly higher in MS brains than control brains (76). Other studies describe
significance higher prevalence of IgG titers directed at the HHV-6 U94 rep homologue
protein and elevated IgM antibody directed against p41/38 HHV-6 early antigen in MS
patients during relapse (77–79). HHV-6 DNA and infectious virus could also be detected
and isolated from the cerebral spinal fluid of MS patients (79,80). Despite these data,
contradicting reports have found no significant differences in DNA and antibody levels
between individuals with MS and controls (81).
Chronic Fatigue Syndrome
Chronic fatigue syndrome (CFS) is a chronic multi-systemic disease
characterized by long-standing fatigue, impaired memory and concentration,
hypersomnia, headache, and musculoskeletal pain (82). Additionally, individuals
suffering from CFS also present with hypothalamic dysfunction and quantitative
encephalography consistent with encephalopathy (83,84). To date, the etiological agent
of CFS has not been established. However, many have suggested that a viral agent
may be a trigger because patients often report having flu-like symptoms prior to CFS
onset (84,85).
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HHV-6 exhibits immunomodulatory effects and has the ability to productively
infect cells of neuronal origin; thus, many have suggested these viruses to be a trigger
for CFS (84). In the literature, there are reports supporting and refuting these claims.
Studies supporting a role for HHV-6 in CFS, indicate a significant increase in antibody
titers to HHV-6 early antigen p41 and late antigen gp110 in affected individuals (86).
Elevated titers suggest viral reactivation; improved cognitive function was also
described with the use of valganciclovir treatment in individuals with elevated HHV-6
titers (83,87). However, other studies found no difference in HHV-6 IgG levels in
individuals with CFS (88)
Research on the role of HHV-6 in CFS pathology is far from complete. For
example, the prevalence of CIHHV-6 in the CFS population has not been fully explored.
CIHHV-6 adds a level of complexity to the question of how HHV-6 affects CFS
pathology because inheritance of the virus may potentially alter an individual’s immune
response and may contribute to the disease pathology.
Drug-Induced Hypersensitivity
Drug-induced hypersensitivity (DIHS)/drug rash with eosinophilia and systemic
symptoms (DRESS) is a rare but severe systemic drug allergic reaction, characterized
by rashes, fever, and lymphadenopathy. Triggers for DIHS/DRESS include
anticonvulsants, some classes of antibiotics, and anti-inflammatory drugs (50,89,90).
Many anticonvulsants, such as valproic acid and carbamazepine, are HDAC inhibitors;
thus, these epigenetic modifiers often lead to the reactivation of latent herpesviruses.
Multiple studies have linked HHV-6 to DIHS; HHV-6 replication has been detected in
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DIHS skin lesions and anti-HHV-6 IgG and IgM has also been detected in patient
serum. The presence of both HHV-6 specific IgM and IgG during DIHS, suggests that
primary HHV-6 infection and HHV-6 reactivation may be contributing factors to the
syndrome.
HHV-6 Detection in Clinical Samples
The most common method for detecting primary HHV-6 infection is indirect
immunofluorescence to detect anti-HHV-6 IgM and IgG antibodies (91,92). Additionally,
active replication may be detected by PCR or RT-PCR for the detection of viral DNA or
RNA in plasma or serum or whole blood (92–95). Following primary infection, IgG
antibodies often persist and IgM antibody diminish and do not always reappear with
reactivation. Therefore, quantitative PCR is most often used for detecting viral
reactivation or reinfection. Different methodologies, however, must be used to detect
active HHV-6 replication in individuals with CIHHV-6.
In contrast to transient infections with HHV-6, CIHHV-6 positive individuals
exhibit a persistent high viral load (1x 106-1 x 107 copies/ml) in PBMCS, and hair
follicles, leukocytes, and other clinical samples are also positive (34,96,97). The
antibody response to HHV-6 in CIHHV-6 harboring individuals is variable with regards to
the presence of IgG antibodies in the serum of these individuals (37,38). In vitro studies
and clinical reports indicate that HHV-6 may be reactivated from its integrated form
(15,36); however detection of reactivation in samples from individuals with CIHHV-6 is
difficult using PCR based methodologies. HHV-6 antibody response during reactivation
is also variable and may yield inconclusive results. Detection of mRNA, however, seems
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to be a promising marker for viral reactivation; thus, several research groups
successfully detected active HHV-6 replication using reverse-transcriptase PCR based
assays (30,35,93–95,98).
Conserved and Unique Genes of HHV-6
The genomes of HHV-6A and HHV-6B are colinear to human cytomegalovirus
and to date there are greater than sixty open reading frames with known or implied
function (99). Protein-encoding open reading frames occur within the unique length
region as well as the direct repeats of the virus, and proteins are encoded on both
strands of the viral genome. Similar to other herpesviruses, the majority of genes
encoded by HHV-6A and HHV-6B are conserved across all herpesvirus subfamilies.
Conserved herpesvirus genes include tegument and capsid proteins, and proteins
essential for the helicase/primase and DNA polymerase complex. Additionally, one
block of genes at the left end of the virus (U2 to U19) is specific to betaherpesviruses;
and another seven other genes are unique to roseoloviruses (U20, U21, U23, U24,
U24A, U26, U100). There are only five genes that are unique to HHV-6A/6B. (Table 2)
HHV-6 Interstrain and Intrastrain Variation
To date, four HHV-6 genomes have been completely sequenced (Table 3)
(5,6,9,100). Whole genome sequence comparison has been performed comparing the
two B viruses, HST and Z29, to HHV-6A U1102 (5,6). The sequencing for HHA-6A GS
has been completed and made available recently; however, the genetic relationships
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Figure 4: A Diagram of the HHV-6 Genome. The HHV-6 genome includes 7 gene
blocks with are conserved across all herpesvirus subfamilies (numbered open arrows),
as well as one gene block specific to betaherpesviruses. The black boxes indicate the
perfect telomere repeats, while the gray box represents the imperfect telomere repeats.
(5,99)

Table 2: HHV-6 Specific Genes
Gene ID
DR3
U6
U22
U83
U94

Gene Product
MicroRNA
Unknown
Glycoprotein
Chemokine/Cytokine
Parvovirus rep homologue

between the GS and other sequenced HHV-6A viruses have yet to be been elucidated.
Full genome studies focusing on intrastrain variation are also limited. However, studies
have looked at the nucleotide and amino acid sequence variation of several genes in
clinical samples, and there are preliminary data on partial differences between HHV-6B
Z29 and HHV-6B HST (5,6).
The amino acid identity between HHV-6A and B isolates averages approximately
90% (5,6). The center of the genome (U32-U77) is highly conserved, and the most
conserved open reading frames include the genes encoding the helicase/primase
complex (U77), capsid assembly proteins (U40), and the putative terminase (U60/66).
The region of greatest divergence is the right end of the genome, which encodes open
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reading frames U86 to U100 as well as the three major repetitive elements, R1, R2, and
R3. The amino acid identity in this region is 72% (5). Other variable genes, such as U47
(glycoprotein) and the U83 (chemokine) are scattered throughout the genome and are
generally located between conserved herpesvirus gene blocks (Figure 4). In addition to
differences in protein encoding genes, HHV-6B viruses have an expanded DR region,
when compared to HHV-6A U1102 (5,6).
A few studies have focused on the nucleotide and amino acid sequence
divergence in clinical samples. Sequence analysis from clinical strains isolated from the
United States, Japan, Germany, Uganda and Zaire highlights key differences
demonstrating inter and intrastrain variation (101). For the U38 chemokine, the amino
acid identity between HHV-6A U1102 and HHV-6BZ29 is 85.7% (5). Key interstrain
differences are as follows: (1) none of the HHV-6A viruses encode a mature chemokine
with a functional signal peptide (2); the majority ofU83A isolates have a 2 amino acid
truncation at the C-terminus., with U1102 being the exception (101). Upon further study,
HHV-6B viruses could further be divided into groups, one group with a shortened signal
peptide and the other group, which includes HHV-6BHST and HHV-6BZ29 with a full
length signal peptide. Intrastrain amino acid divergence for the B isolates ranged from 0
to 3.5% (101).
Glycoproteins B and H are highly conserved in the herpesvirus family; however,
distinct differences in nucleotide and amino acid sequences between variants clearly
segregate HHV-6A viruses from HHV-6B. Intrastrain variation in the amino acid
sequences of 31 HHV-6B clinical samples was 0.9% and 0.3% for gB and gH,
respectively (102). Despite the small magnitude of difference within strains, the B
18

isolates could be further segregated into two groups based on gB and gH sequences.
The segregation, however, differed depending on which gene was analyzed, suggesting
that intrastrain recombination between HHV-6B viruses may occur (102).
Other studies on inter and intrastrain variation in clinical samples focused on
envelope glycoprotein O (U47), and the polymerase processivity factor (U27).
Sequencing of the hypervariable gene U47 gene is useful for genotyping HHV-6 viruses
in clinical samples (63,103). Amino acid sequence identity between U1102 and GS is
97.5%, while the identity to HHV-6B Z29 is only 89%. Sequencing results of a portion of
the U47 reports up to 6% variation within HHV-6 variants for this region and up to 8%
variation between groups (103). In other studies by Bonnafous et al., the interstrain
variation for the U27 DNA polymerase processivity factor gene is 7.6% when comparing
HHV-6A and HHV-6B clinical isolates, while intrastrain differences were 1.2% and 0.3%,
for A and B isolates, respectively (104).

Table 3: Fully Sequenced HHV-6 Strains
Strain
HHV-6A U1102
HHV-6A GS
HHV-6B Z29
HHV-6B HST

Genbank Accession
NC_001664
KC465951
NC_000898
AB021506
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Geographic Location
of Isolation
Uganda
North America
Zambia
Japan

Adaptive Immune Response to HHV-6 Infection
Cellular Response to HHV-6
Both CD4+ and CD8+ HHV-6 specific T-cells have been isolated from the
PBMCs of healthy donors. In the case of both CD4+ and CD8+ the frequency of HHV-6
specific T-cells is low, but the responding population could be expanded in vitro (105–
107). Expanded CD4+ and CD8+ populations characteristically secrete IFNγ and TNFα,
while also performing cytolytic functions mediated by the secretion of perforin (CD4+) or
granzyme B (CD8+) (105,106,108). Additionally, CD8+ clones were found to also
secrete granulocyte macrophage stimulating factor. Studies on T-cell response to HHV6 have identified 8 HLA-DR restricted CD4+epitopes and 5 HLA-A restricted CD8+
epitopes (105–107).

Table 4: HHV-6 T-cell Epitope Specificity (105–107)
CD4+
Gene ID
U11
U14
U38
U48
U54
U57
U71
U90

Gene Product
Tegument/Antigenic virion protein
Phosphorprotein 85
DNA Polymerase
Glycoprotein H
Virion transactivator
Capsid Protein
Myristolated virion protein
Immediate early transactivator
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+
+
+
+
+
+
+
+

CD8+
+
+
+
+
+

Antibody Response to HHV-6
During primary infection, anti-IgG and anti-IgM antibodies are produced, with IgM
antibodies being the first to be detected (67,91). IgG titer begins to increase about one
week post infection and peaks a week later. Additionally, there is an increase in IgG
avidity over the course of infection (60,67).
The antibody response to HHV-6 in CIHHV-6 harboring individuals has not been
clearly defined; thus, studies in the future should focus on this topic. However, one
study by Tanaka-Taya et al. measured antibody titer to two HHV-6 antigens (IE-A and
glycoprotein gB) in the PBMCs of CIHHV-6 individuals and compared the response to
that of healthy non-CIHHV-6 individuals (38). Interestingly, 57% of individuals with
CIHHV-6 had antibodies to the IE-A antigen present in the serum, while IE-A antibodies
were undetectable in non-CIHHV-6 individuals. On the other hand, 14% of CIHHV-6
versus 60% of the healthy individuals had an antibody response to gB (38).
Glycoprotein B is considered one of the major neutralizing epitopes and variant specific
gB antibodies have been detected (109). The absence of gB antibodies or reduced antigB titers may reduce the ability of CIHHV-6 individuals to mount an immune response to
an exogenous HHV6 infection.
Treatment of HHV-6 Associated Diseases
Primary HHV-6 infections are usually self-limiting and do not require antiviral
therapy. However, in the case of complications due to viral reactivation antiviral
treatment may be necessary until symptoms subside. HHV-6 viruses do not respond to
the nucleoside inhibitors acyclovir and pencyclovir, in vitro or in vivo (110). Patients
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experiencing HHV-6 related post-transplant complications, such as encephalitis,
respond best to valganciclovir and foscarnet, or the pyrophosphate analogue, cidofovir
(53,110,111). Additionally, a preliminary study by Montoya et al. recently described the
successful treatment with valganciclovir of two related patients with chromosomally
inherited HHV-6 who were exhibiting neurological symptoms in conjunction with active
HHV-6 replication (83). However, to date no drugs have been approved by the FDA
specifically for the treatment of HHV-6.
Coinfection and Superinfection with Herpesviruses
Reinfection with HHV-6 has been noted, suggesting that despite the
development of neutralizing antibodies and T-cell immune responses the virus is able to
subvert the immune system. Indirect evidence supporting the possibility of co-infection
and superinfection in children comes from a study by Bates et al (63). In this study,
febrile and non-febrile children in Zambia were tested for HHV-6 prevalence and the
detected viruses were genotyped by determining the amino acid sequence of the U47
envelope glycoprotein O. In this study, co-infections were reported at a rate of 21% to
50%, in non-febrile and febrile children, respectively. Thirteen percent of the non-febrile
children had co-infection with both HHV-6A and HHV-6B at 18 months of age; coinfection with both variants was associated with an elevated viral DNA load in the serum
of nearly four times the average for a single infection. HHV-6 reinfection was also noted
in a study of children in the United States (112). More recently, Burbelo et al. designed
a novel HHV-6 variant specific serological test for the detection of HHV-6A and HHV6B U11 antigen (88). In a screening of 25 African serum samples, 50% of the samples
HHV-6A seropositive and 80% were HHV-6B seropositive. This implies that a fraction of
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the individuals in this study had either been reinfected by another HHV-6 virus or
superinfected with both HHV-6 variants prior to seroconversion. The information on
reinfection and superinfection in CIHHV-6 positive individuals is limited; thus, no reports
of this nature have been reported prior to the current study.
Human cytomegalovirus, another betaherpesvirus, is associated with
encephalitis, retinitis, and other diseases in the immunocompromised. In individuals with
a functional immune system, CMV establishes persistent infection in salivary gland
tissue and myeloid cells and viral shedding may occur for years after primary infection
(113). Despite robust antibody production in response to CMV and the high frequency of
CMV-specific T-cells in the peripheral blood, asymptomatic CMV reactivation is frequent
in healthy individuals and constant immune surveillance is needed to control the virus
(114–116). Additionally, mixed infections frequently occur and individuals with persistent
infection may be superinfected with additional strains of the virus (117). The key to CMV
persistent infection and superinfection is the subversion of the host immune system by
viral proteins which inhibit MHC function (118). Furthermore, a functional consequence
of persistent CMV infection is immunosenescence: excessive expansion of CMVspecific T-cell clones lead to premature senescence and reduced T-cell responsiveness
(119).
Development of Immune Tolerance
During development, multiple mechanisms are used to ensure self-tolerance. In
the thymus, T-cells that are specific to self-antigens are deleted by negative selection
(120). In the periphery, presentation of self-antigens in the absence of co-stimulatory
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molecules leads to T-cell anergy or inactivation (121). For B-cells, self-tolerance occurs
by one of three mechanisms: receptor editing to replace self-reactive receptors, deletion
of self-reactive clones, and anergy (122).
Inheritance of HHV-6 presents the possibility for immune tolerance to viral
antigens. CIHHV-6 reactive T-cells may be deleted by negative selection during
development or T-cell anergy may be induced. Humoral responses may also be lower, if
viral genes are expressed during development and are recognized as self. Alternately,
in the event that reactivation of the inherited virus occurs after birth and CIHHV-6
specific antibodies or T-cells are developed. These individuals may still be susceptible
to superinfection if the exogenous virus differs significantly from the inherited virus.
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OBJECTIVES AND HYPOTHESIS OF THE CURRENT STUDY
This study focuses on a unique patient population that displays chronic fatigue
syndrome-like symptoms, such as CNS dysfunction (impaired concentration and short
term memory, and mild dementia), headache musculoskeletal pain, headache, and
long-standing fatigue and has inherited HHV-6. The central hypothesis of this study
is that these CIHHV-6 harboring patients suffer from CFS-like symptoms because
of reactivation/active replication of HHV-6. Investigation of this hypothesis will be
accomplished by three specific aims.
1: Test the ability of various compounds to cause reactivation of CIHHV-6 in vitro.
The rationale for this is aim was that quantitative PCR is unable to differentiate between
actively replicating HHV-6 virus in patients with CIHHV-6; therefore, it is essential to
develop an assay to detect replicating virus.
2: Test in vivo reactivation of latent HHV-6 in patient samples. In this part
epigenetic modifiers will be used to induce replication of latent HHV-6 in patient
samples, and the induced virus will be characterized and compared to prototype HHV-6
strains and to the inherited virus.
3: Test the efficacy of antiviral treatment in suppression of HHV-6
reactivation/replication in patients with CFS-like symptoms. The purpose of the final aim
is to correlate HHV-6 replication status with neurological symptoms and evaluate the
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effect of short term and long term antiviral treatment. Additionally, the prevalence of
CIHHV-6 will be assessed in a population of individuals displaying CFS-like symptoms.
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MATERIALS & METHODS

Note to Reader
Portions of this chapter have been previously published in Journal of Medical
Virology, 2013, 85(11): 1940-1946 and has been reproduced with permission from
Wiley Periodicals, Inc.
Study Subjects, Treatment, Statistical Analysis
Four patients diagnosed with inherited HHV-6 provided written informed consent
prior to the start of this study, and the study was approved by the Institutional Review
Board. All subjects presented with more than 0.5 million DNA copy numbers of HHV-6
in whole blood, with concomitant positive results of HHV-6 in hair follicles as detected
by Viracor-IBT laboratories, Inc. Patients presented with fatigue and neurological
symptoms including, but not limited to, depression, hypersomnia, memory and cognitive
impairment. In this study, patients received therapeutic antiviral therapy consisting of
either twice daily valganciclovir (patients 1, 2, and 3) or 60 mg/kg foscarnet (patient 4)
per day. Patients receiving short term treatment received 900 mg valganciclovir twice
daily; patients receiving long term treatment received 900mg valganciclovir twice daily
for three weeks and 450mg twice daily for three weeks or longer. Blood samples were
collected in Quiagen PAXgene DNA, RNA, and heparin tubes before and during
treatment.
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A two-tailed Fisher exact test was used to determine the significance of CIHHV-6
prevalence among a cohort of 337 US adult patients suffering from neurological
symptoms.
Isolation of RNA & DNA from Blood or PBMCs
For RNA isolation, patient whole blood was collected in Quiagen PAXgene blood
RNA tubes and incubated at room temperature for at least 2 hours prior to processing.
Cells from whole blood were pelleted by centrifugation for 10 minutes at 3,780 rpm
(3,000xg) in a Fisher Scientific accuSpin 1R (rotor #3450). Alternately, PBMCs or
immortalized T-cells were pelleted at 1,500 rpm in a Fisher Scientific accuSpin 1R (rotor
#3450). After collection by centrifugation, cells were homogenized with TRIzol Reagent
(Invitrogen), separated with chloroform, precipitated with isopropanol, and washed with
75% isopropanol. The pelleted RNA was resuspended in diethyl pyrocarbonate (DEPC)treated water.
For DNA isolation, patient whole blood was collected in Paxgene blood DNA
tubes, and DNA was isolated using Wizard Genomic DNA Purification Kit (Promega).
Alternately, for DNA isolation from cells, cells were pelleted at 1,500 rpm in a Fisher
Scientific accuSpin 1R (rotor #3450) and DNA isolation was also performed using
Wizard Genomic DNA Purification Kit (Promega), according to the manufacturers
protocol.
Isolation of DNA from Agarose Gel and Cloning
Amplified PCR products were separated on a TBE agarose gel and visualized
using ultraviolet light. Bands corresponding to the PCR-amplified products were excised
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and DNA was isolated from the gel fraction using the Wizard SV Gel and PCR Clean-Up
System (Promega). The DNA was then TA cloned using the PCR4 TOPO (Invitrogen) or
pGEMT-Easy (Promega) cloning system. For DNA generated using the Primestar High
Fidelity Polymerase, an A-tailing reaction was performed prior to TA cloning. Briefly, the
purified PCR fragment was incubated with 0.2mM dATP and 5 units of RedTaq
Polymerase (Sigma) for 30 minutes at 70 ºC. The A-tailed product was then ligated with
the TA vector
For PCR4 TOPO cloning system, 1.5µl of the ligated DNA was mixed with 50µl of
competent E. coli ElectroMAXDH10B strain (Invitrogen) and incubated on ice for 30
minutes. The chilled DNA/bacteria mixture was then put into a 1mm gap cuvette and
electroporated at 1500V. The transformation mixture was then incubated in SOC broth
for 1 hr at 37º C with rotation, and the incubated mixture was plated on Luria Burtani
(LB) plates containing 50 mg/ml kanamycin and 40mg/ml X-gal (5-bromo-4-chloro-3inodyl-β-D-galactopyranoside). The composition of LB plates is as follows: 10g tryptone
and sodium chloride, 5g yeast extract per 1 liter of water, pH 7.5). The plates were
incubated for 14-16 hours at 37 C.
For the pGEMT-Easy cloning system, 2µl of ligated DNA was mixed with 40µl of
competent JM109 (Promega) and incubated on ice for 20 minutes. The DNA/bacteria
mixture was then incubated at 42ºC for 45 to 50 seconds. The transformation mixture
was then incubated in SOC broth for 1.5 hr at 37º C with rotation. The incubated mixture
was plated on LB plates containing 100 mg/ml ampicillin with 80µg/ml X-gal and 0.5mM
IPTG (Isopropyl-β-D-thiogalactopyranoside). The plates were then incubated for 14-16
hours at 37º C.
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The following day, white colonies were picked and incubated in 4 ml of LB
containing 50mg/ml kanamycin or 100mg/ml ampicillin and incubated with shaking for
16 hours. Three milliliters of liquid cultures were used for plasmid isolation using the
Fermentas Gene Jet Plasmid Miniprep Kit. Restriction enzyme digestions with EcoRV
were performed on isolated plasmids to confirm the presence of the correct sized
inserts.
HEK293 Single Cell Clones & Fluorescent In Situ Hybridization
HEK293 cells were infected with HHV-6A U1102, and single cell clones were
obtained by limited dilution and seeding in a 96 well plate. Individual clones were
expanded and maintained in DMEM (Dulbecco’s Modified Eagles Medium) with 10%
FBS (Fetal Bovine Serum), supplemented with 50µg/ml gentamicin. Genomic DNA was
isolated from each clone using the Wizard Genomic DNA purification kit. To confirm
HHV-6 infection, PCR assay was performed to detect HHV-6 ORF U94 and subsequent
agarose gel electrophoresis.
To confirm integration of the HHV-6A genome, single cell HEK293 cells were
treated with colcemid and harvested according to standard cytogenetic protocol (123).
Metaphase chromosomes were by hybridized with fluorescein labeled HHV-6A U1102
cosmid probes pMF335-631 and pMF311-12 (124). Five or more metaphase
chromosomes were examined for each cell line. FISH experiments were performed at
the University of Minnesota Cytogenetics Core Laboratory.
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In vitro Reactivation of Integrated HHV-6 and Virion DNA Isolation: Patient
Samples
Patient PBMCs were isolated by density gradient centrifugation (Lymphoprep)
and maintained in RPMI-1640 medium with 10% FBS and 50µg/ml gentamicin and
treated with 10 ng/ml TPA (12-O-tetradecanoylphorbol-13-acetate) and 10ng
hydrocortisone as previously described (15). Patient cells were co-cultured with Molt3 Tcell line for two weeks until the formation of syncytia was observed. Virion particles were
isolated by centrifugation of supernatant from infected cells at 27,000rpm in a Beckman
L7-65 ultracentrifuge (SW41 rotor). Following centrifugation, DNA was extracted using
Wizard Genomic DNA Purification Kit (Promega) or phenol chloroform extraction.
Reactivation of Integrated HHV-6: HEK293 Clones and Assay to Detect Catenated
Genomes
HEK293 cell clones harboring integrated HHV-6A were maintained in DMEM with
10% FBS and with 50µg/ml gentamicin and treated varying concentrations (160 ng/ml,
80 ng/ml, 40 ng/ml, 20 ng/ml or 10 ng/ml) of TSA for three days. Alternately, single cells
were treated with the same concentrations of sodium butyrate, carbamazepine, or
valproic acid. Untreated cells were used as a negative control in all experiments.
After treatment, DNA was isolated from the cells using Promega’s Wizard
Genomic isolation, and PCR amplification was performed to detect catenated genomes
(Figure 5). Amplified DNA was separated by agarose gel electrophoresis, blotted onto
nitrocellulose, and probed with α32-dATP DR probes or with α32-dATP HHV-6A BAC
vector probe.
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Figure 5: Schematic of PCR Assay for Detecting Catenated Viral Genomes. After
induction with various epigenetic modifiers, PCR will be performed with primers specific
to the unique length of the HHV-6 viral genome. A PCR product will only be generated if
the viral genome is joined in a head –to-tail manner.

cDNA Synthesis and Nested Reverse Transcriptase PCR Assay
Blood samples were collected in PAXgene blood RNA tubes and RNA was
isolated using Trizol reagent. Briefly, 30 ng of total RNA and random primers were used
for first strand cDNA synthesis using the GoScript Reverse Transcription System
(Promega). Alternately, RNA isolated from uninfected or infected Molt3 T lymphocytes
was used as a negative or positive control, respectively. An equivalent of 5ng of total
RNA was used for nested PCR reaction.
Two rounds of PCR were performed to using RedTaq Polymerase (Sigma) and
primers specific to the U100 glycoprotein. For a cellular control, beta actin was amplified
with 30 cycles of PCR. Additionally, a reverse transcriptase null reaction was performed
to ensure the absence of DNA in RNA samples. Amplified products were separated by
agarose gel electrophoresis, stained with ethidium bromide, and visualized using
ultraviolet light in the Gel Doc Molecular Imaging System (Bio-Rad).
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Table 5: Primers Used for Nested RT-PCR and Beta Actin

Primer Name
U100 Outside F (93)]
U100 Outside R (93)
U100 Inside F (93)
U100 Inside R (93)
Beta actin F
Beta actin R

Sequence
5’-CTAAATTTTCTACCTCCGAAATGT-3’
5’-GAGTCCATGAGTTAGAAGATT-3’
5’-ACTACTACCTTAGAAGATATAG-3’
5’-AAGCGCGTGCAGGTTTCCCAA-3’
5’-CTGGAACGGTGAAGGTGACA-3’
5’-AAGGGACTTCCTGTAACAATGCA-3’

Table 6: PCR Cycling Conditions: U100 Nested RT-PCR

Step
Initial denaturation
Denaturation
Annealing
Extension
Final Extension

Temperature (ºC)
94
94
43 (outside)/53
(inside)
72
72

Time (minutes)
2
1
2
1.5
5

Number of
cycles
1x
30x

1x

Table 7: PCR Cycling Conditions: Beta Actin
Step
Initial denaturation
Denaturation
Annealing
Extension
Final Extension

Temperature
(Celsius)
94
94
52
72
72

Time (minutes)
2
1
2
0.5
5

Number of
cycles
1x
30x
1x

PCR Amplification for Sequence Comparison or Detection of Viral DNA in Infected
Cells
Selected HHV-6 open reading frames were amplified by PCR amplification using
DNA isolated from whole blood or PBMCs as a template. Primestar High Fidelity
33

Polymerase (Takara) was used to perform each reaction. Two step or three step
amplification was performed, according to the manufacturer’s protocol. To confirm viral
infection, ORF U94 was amplified by PCR with RedTaq polymerase and using DNA
isolated from HHV-6A infected HEK293 single cell clones as a template.
Sequencing
For cDNA sequencing and sequencing for genome comparison clones were
sequenced at the Moffitt Cancer Center Molecular Genomics Core Facility using the
ABI3130XL capillary sequencing instrument. Alternatively, pyrosequencing of virion
DNA was performed at the Recombinant Herpesvirus and HTS sequencing Core
Laboratory at the University of Florida using the Roche 454 GS-FLX Assembly of the
consensus sequence obtained from pyrosequencing was assembled using HHV-6A
U1102 as a reference.
Restriction Digest and Southern Blot for Comparison of Inherited and Reactivated
Viral Genomes
For evaluating the heterogeneity in inherited HHV-6 strains, 5 µg of cellular DNA
from patient PBMCs or 1ng of virion DNA was digested with SacI. For comparison of the
reactivated HHV-6 strain to the U1102 prototype strain, 45 ng of virion DNA was
digested with BamHI and SacI. Digested DNA was separated agarose gel run in 1x TBE
buffer, stained with Sybr Green (Manufacturer) or ethidium bromide and visualized
using the GE Typhoon Imager or Bio-Rad Geldock, respectively.
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Southern Blot
Preparation of Gel for Transfer
After separation of DNA on an agarose gel run in 1xTBE Buffer, the gel was
incubated under the following conditions with gentle rocking to prepare the gel for DNA
transfer.
Table 8: Southern Blot Gel Preparation
Step

Solution

Depurination
DNA
denaturation
Neutralization

0.25M HCl
1M NaCl, 0.5M
NaOH
1.5M NaCl, 0.5M
TrisHCl

Incubation time
(minutes)
10
15

Number of
washes
2
2

15

2

Transfer
After washing was completed, the gel was transferred to Hybond C mixed ester
nitrocellulose by vacuum blotting for 30 minutes (125). A 10x saline sodium citrate
(SSC) solution was used as a transfer agent to prevent gel from drying during transfer.
After transfer, the DNA was immobilized by baking the membrane at 80ºC for one hour.
Preparation of α32-dATP Probe
An HHV-6A BAC vector was used to generate an α32P-dATP probe (4). Initially,
a combination of 20-100ng BAC vector DNA, 1.5µg random primers (Promega) was
heated at 100 ºC for 3 minutes. Following denaturation, 50 µM dNTP-dATP, 5U DNA
Polymerase I Klenow, DNA polymerase buffer (to a final concentration of 1x), and 50
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µCi α32-P dATP (Perkin Elmer) was added. The complete probe mixture was incubated
for 4 hours at room temperature (22-25ºC) and then the reaction was stopped with 45
microliters stop buffer (20mM NaCl, 50mM EDTA, 20mM Tris, 1% SDS)

Table 9: Primers Used for Sequence comparison

Primer Name
U11F
U11R
U15F
U15R
U18F
U18R
U20F
U20R
U31F
U31R
U38F
U38R
U47F
U47R
U79F
U79R
U83F
U83R
U86F
U86R
U90F
U90R
U91F
U91R
U95F
U95R
U100F
U100R

Sequence
5’-TCACGACGCGATCGCTGACTCGC-3’
5’-ATGGATCTGCAAAGACATCCGATTCCG-3’
5’-CGCAGAACCAGACGCTCAACGG-3’
5’-ACGGAGAGCTGTCGTGCTGAGCGG-3’
5’-CTAACGACACTGGGAATGAACGCTA-3’
5’- CTCTTGATGCATGTGGCAATTGCTGG-3’
5’-CTGCAACATGCGCGCCAGTTCATCACCGG-3’
5’-GGCCGTACCTTTCTTCGACGTG-3’
5’-CACGAAACAATGCGCCAGCATC-3’
5’-CGTCAAGAAGTTGTTACGGCTTG-3’
5’-TCACATTACCTCTGCAATAGCAG-3’
5’-CCTTCGTCTTCCGAGTCTCATGC-3’
5’-CCAGGTAGAGTTGCGTTAGCCTC-3’
5’-CATTGTGGTCAACTCACCCGACATG-3’
5’-CGTGCGCATAAAAGGACGTTG-3’
5’-CCCAATCAATTGGAACATTCTG-3’
5’-GAGAAGGTTAGTAATATGAGTG-3’
5’-CTCTCTCATGATAAACGCG-3’
5’-CCACGGCGAGATTGTTGATC-3’
5’-GCACACCACGCACAATCGG-3’
5’-CTGAATACTTGACATCTGTATAAGG-3’
5’-GCGGTGTCTCAATTTGCATC-3’
5’-CTTTGCAGAGATTCTCTGCTTGCAC-3’
5’-GTCACATCGATTGCATCCCATC-3’
5’-CCTATCGTTGCGCTGGGAATTCC-3’
5’-GGTAGATTGGATCCAACGGCCTTTTG-3’
5’-CAGAAAGGCCGTTGGATCCAATCTACC-3’
5’-CCGTCGTCATAGGATCTGTTTCGCG-3’
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Prehybridization & Hybridization
The nitrocellulose membrane with the immobilized DNA was incubated in 10ml
prehybridization buffer at 42º C with rocking for 10-30 minutes. While the membrane
was being incubated, 10ml of the hybridization buffer was boiled with the α32P labeled
probe. The membrane was then incubated with the hybridization/probe mixture for 16
hours at 42ºC with gentle rocking.
Table 10: Prehybridization and Hybridization Buffers for Southern Blot

Formamide
20x SSC
50x Deinhardt’s Solution
Sonicated salmon sperm
DNA
1M NaPO4
20% SDS
Dextran sulfate
Water

Prehybridization
25ml
12.5ml
5ml
2.5ml

Hybridization
25ml
12.5ml
1ml
0.5ml

2.5ml
0.25ml
N/A
2.5ml

0.75ml
0.25ml
10ml
N/A

Following incubation, the membrane was washed three times in a heated wash
buffer (55-60ºC) containing 0.1x SSC, 0.1% SDS solution. The washed membrane was
wrapped in plastic wrap and exposed to a phosphoimager screen for 4 hours- 5 days.
The image was developed using a GE Typhoon Imager.
Alignment of nucleotide sequences
Complete alignment of nucleotide sequences was performed using ClustalX
2.0.10. Parameters were as follows for pairwise alignments: Gap opening 10, Gap
extend 0.1, Protein weight matrix Gonnet 250, DNA weight matrix: IUB. For multiple
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alignments: Gap opening g10, Gap extend 018.2, Delay divergent sequence 30%, DNA
transition 0.5, Gonnet series, DNA weight matrix: IUB.
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RESULTS

Note to Reader
Portions of this chapter have been previously published in Journal of Medical
Virology, 2013, 85(11): 1940-1946 and has been reproduced with permission from
Wiley Periodicals, Inc.
AIM 1: Test the Ability of Various Compounds to Cause Reactivation of Integrated
HHV-6 In Vitro
Generation of HEK293 Single Cell Clones
To develop an in vitro model of HHV-6 latency, HEK293 cells were infected with
HHV-6A U1102. By limited dilution, single cell clones were isolated in individual wells of
a 96-well plate and expanded. Although multiple single-cell clones were generated,
some clones stopped dividing for an unknown reason. Originally 50 viable single
HEK293 cells were isolated, and ten of these were initially positive for HHV-6. However,
seven of the clones lost the viral genome after prolonged subculturing. Three clones
stably maintained the HHV-6A genome, as indicated by PCR amplification of ORF U94,
as reported previously (15). The viable clones were designated C8, D2, and G6. As an
additional means of confirming HHV-6 integration, fluorescent in situ hybridization
(FISH) was performed using cosmid probes specific to large regions of the HHV-6
genome. FISH for all three clones revealed hybridization of HHV-6 at the ends of 4',639

diamidino-2-phenylindole (DAPI) stained metaphase chromosomes, confirming viral
integration into the telomere ends of the chromosomes (Figure 6). Two clones, D2 and
G6 had one integration site; the final clone C8 had two integration sites (Figure 6).

Figure 6: Fluorescent In Situ Hybridization of HEK293 Clones Infected with HHV6A. Metaphase chromosomes of three HEK293 single cell clones with integrated HHV6 were stained with DAPI (blue). In this figure, hybridization was performed with HHV-6
cosmid probes pMF311-12 and pMF335-631 which were labeled with fluorescein
(green).

Detection of Circularized Viral Genome During Reactivation
Both HHV-6A and HHV-6B preferentially integrate into the telomeres as a means
of establishing latency (15,18). The ability to reactivate from latency is essential to the
spread of viral infection. To investigate the effect of epigenetic modifiers on the
replication states of latent HHV-6 virus, HEK293 single cell clones were treated with
varying concentrations of trichostatin A, sodium butyrate, valproic acid, or
carbamazepine for three days. Once cytopathic effect was observed, DNA was isolated
from the treated cells. To confirm the reactivation of integrated virus, a PCR-based
assay was developed to detect the circularized HHV-6 genome. The designed primers
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were specific to the unique length of the viral genome and oriented in opposite
directions. Therefore, a PCR product would only be generated in the event that
circularization of the viral genome occurs. Southern blotting was then performed on the
PCR generated products using either and probed with an α32P labeled probe
surrounding the viral DRs or with an α32P HHV-6A BAC vector probe.
Initially, all three single cell clones were treated for three days with varying
concentrations (160 ng/ml, 80 ng/ml, 40 ng/ml, 20 ng/ml or 10 ng/ml) of TSA or the
other epigenetic modifiers, sodium butyrate, valproic acid, or carbamazepine to
determine their ability to reactivate from the integrated form. Southern blotting and
hybridization with radiolabeled BAC vector probe revealed that of the three clones, only
the D2 clone was capable of reactivation, as indicated by the variation in banding
patterns after development of the Southern Blot (Figure 7). Furthermore, of the
epigenetic modifiers tested, only TSA induced the reactivation of latent HHV-6A virus
(Figure 8). These results indicate that in some cases integration of HHV-6 may be a
dead end phenomenon. Possible explanations for this will be presented in the
discussion.
To qualitatively asses the variation in size of the direct repeat during HHV-6
reactivation, Southern blotting was performed on TSA-treated D2 clone as described
above; however, a probe specific to the unique regions of the viral genome surrounding
the DRs was used. Upon induction, with variable concentrations of TSA, multiple distinct
bands were detected after hybridization. Differences in DR size at each TSA
concentration demonstrate that upon circularization there is variation in the DR length
(Figure 9). Possible reasons for this will be discussed at a later point.
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Figure 7: Trichostatin A Effectively Induces the Reactivation of HEK293 Clone D2.
HEK293 single cell clones (C8, D2, or G6) latently infected with HHV-6A were treated
with varying concentrations of TSA (Lane 1: 160 ng/ml, Lane 2: 80 ng/ml, Lane 3: 40
ng/ml, Lane 4: 20 ng/ml, Lane 5: 10 ng/ml Lane 6: untreated). Following induction, PCR
was performed to detect the formation of viral concatemers. PCR products were
separated by electrophoresis, blotted onto nitrocellulose and probed with a α32P HHV6A BAC vector probe.
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Figure 8: TSA is Most Effective at Inducing the Reactivation of Latent HHV-6
Virus. HEK293 cells latently infected with HHV-6A were treated with varying
concentrations of four epigenetic modifiers: sodium butyrate, carbamazepine,
Tricostatin A, and valproic acid. (Lane 1: 160 ng/ml, Lane 2: 80 ng/ml, Lane 3: 40 ng/ml,
Lane 4: 20 ng/ml, Lane 5: 10 ng/ml Lane 6: untreated). Following induction, PCR was
performed to detect the formation of viral concatemers. PCR products were separated
by electrophoresis, blotted onto nitrocellulose and probed with α32-dATP HHV-6A BAC
vector probe.
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Figure 9: During Reactivation DR length is Variable. Uninfected HEK293 or
HEK293 cells latently infected with HHV-6A were treated with varying concentrations of
TSA (160 ng/ml, 80 ng/ml, 40 ng/ml, 20 ng/ml or 10 ng/ml) or left untreated. Following
induction, PCR was performed to detect the formation of viral concatemers.
Additionally, the concatemer-formation assay was also performed on lytic infected or
uninfected Jjhan T-cells. PCR products were separated by electrophoresis, blotted onto
nitrocellulose and probed with a α32-dATP DR probe.

AIM 2: Test if Inherited HHV-6 in Patient Samples can be Reactivated In Vitro
Reactivated virus is infectious
In vitro experiments with HEK293 clearly demonstrated that HHV-6 can be
reactivated from its latent form in HHV-6A containing cell lines. In the second aim of this
project, the goal was to test if inherited HHV-6 in patient samples could be reactivated in
vitro. Here, we used T-cells isolated from a patient with inherited HHV-6 who resides in

44

the United States. In a previous publication, confirmed HHV-6 integration at 18q23 and
vertical transmission of the virus from parent to this patient, who was previously
designated Family 1/Sibling 2 (15). In attempts to induce the inherited virus, PBMCs
isolated from whole blood obtained from Family 1/Sibling 2 were treated with TPA and
hydrocortisone, a combination previously shown to reactivate integrated HHV-6, while
having limited amounts of toxicity (15). During induction, the treated PBMCs were cocultured with Jjhan or Molt3 T cell lines until primary cells reached their replication limits
and died. Co-cultured cells were observed for visible cytopathic effect. As a control,
PBMCs latently infected withU1102 were also induced with TPA and hydrocortisone.
Visible cytopathic effect indicates that the induced virus is infectious (Figure 10).
Reactivated virus is distinct from HHV-6A U1102
The reactivated virus from Family 1/Sibling 1 was confirmed to be an HHV-6A
strain by PCR analysis. In primary molecular analysis, the reactivated viral genome was
compared to the HHV-6A U1102 laboratory stain. Restriction enzyme digestion and
Southern blot analyses indicated that the viral genome was similar, but distinct from the
U1102 strain. When probed with a radiolabeled BAC vector, a unique restriction pattern
was observed, although the majority of visualized bands were colinear to the U1102
fragments (Figure 11).
Nucleotide and amino acid characterization of the reactivated virus
To fully characterize the reactivated viral genome, we performed pyrosequencing
on the isolated virion DNA. The generated consensus sequence was assembled using
the HHV-6A U1102 genome as a reference. However, there were gaps in the nucleotide
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Figure 10: TPA/hydrocortisone Induced Virus from Patient PBMCs is Infectious.
PBMCs latently infected with HHV-6 were treated with 10ng TPA /Hydrocortisone and
co-cultured with uninfected T-cells. Visible cytopathic effect indicates that the induced
virus is infectious.
sequence, most notable in the regions surrounding the repetitive elements in the viral
genome. As needed, select open reading frames were cloned and sequenced to
complete the nucleotide sequence. Amino acid sequences were deduced using the
Expasy translate tool, and both nucleotide and amino acid sequenced were aligned
using Clustal Omega. In this study, the reactivated viral genome was compared to HHV6A U1102, HHV-6A GS, and HHV-6B Z29.
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Figure 11: Reactivated Virus Isolated from Family 1/Sibling 2 is Distinct from
HHV-6A U1102. Virion DNA isolated from the PBMCs of Family 1/Sibling 2 and HHV-6A
U1102 were digested using SacI and BamHI. Fragments were separated by
electrophoresis, blotted onto nitrocellulose and probed with a radiolabeled HHV-6A
U1102 BAC clone.
The nucleotide sequence generated by pyrosequencing was 156.6 kbp in length.
This length was comparable to the HHV-6AGS which is 156.9 kbp in length. BothHHV6A GS virus and this reactivated virus were shorter than the HHV-6A U1102 genome
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and the HHV-6B Z29 genome, that are 159.3kbp and 162kbp, respectively. Similar to
reports comparing HHV-6A U1102 to HHV-6B Z29, there was noted divergence in the
length of the repetitive regions within the viral genome. The reactivated virus was found
to have a shortened DRL and DRR when compared to U1102, GS, and Z29. However
when compared to HHV-6A GS, the R3 region, located between open reading frame
U91 and U94, was approximately 300bp longer. On the other hand, the repetitive R1/
R2 and R3 of HHV-6AU1102 were approximately 250bp and 420bp longer than the
reactivated virus, respectively.
Previous publications have thoroughly covered the difference in nucleotide and
amino acid sequence between the HHV-6A U1102 and HHV-6B Z29 strain (5,6). To
evaluate the level of interstrain variation, we focused on analyzing the differences
between the reactivated virus and the two HHV-6A strains, GS and U1102. The
reactivated was more closely related to the GS (>99% nucleotide identity) isolate than
U1102 (97% nucleotide identity). At the nucleotide level, all open reading frames were
greater than 99% identical to the HHV-6A GS. Of the 83 open reading frames analyzed,
only eleven genes had predicted amino acid sequences that were identical for the
reactivated virus and both HHV-6A laboratory strains (Table 11). Interestingly, three of
these genes are neither located within the herpesvirus core gene blocks, the
betaherpesvirus gene block, nor conserved between Roseoloviruses. These genes
were U47A, U60, and U63. The lack of divergence suggests they may be important to
the biological properties of the HHV-6A viruses. These genes will be further discussed
at a later point. The nucleotide identity between GS and the reactivated virus ranges
from 99 to 100%, while the amino acid identity ranges from 97 to 100%. The nucleotide
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identity between the U1102 and the reactivated virus ranges from 97% to 100%, while
the nucleotide identity ranges from 92% to 100% (Table 12). Interestingly, the predicted
U18 envelope glycoprotein and the predicted U20 membrane protein nucleotide
sequences had early stop codons. The predicted U18 amino acid sequence was 66
amino acid shorter than HHV-6A GS and predicted for HHV-6A GS and U1102, while
the U20 amino acid sequence was 188 shorter than the HHV-6 GS and U1102 strains
(Figure 12 & 13).

Table 11: Open Reading Frames with 100% Identity Between Reactivated Virus,
HHV-6A GS and HHV-6A U1102
Open Reading Frames with 100% Amino Acid Identity
Gene ID
Gene Product
U24A
U25
U29
U32
U35
U47A
U48
U56
U60
U63
U75

Protein U24A
Tegument protein UL43
Capsid triplex subunit 1
Small capsid protein
DNA packaging protein UL33
Envelope glycoprotein 24
Envelope glycoprotein H
Capsid triplex subunit 2
DNA packaging terminase subunit 1
Protein UL92
Tegument protein UL7

Conserved
Gene?
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
No
No
Yes

The Virus Reactivated from Patient PBMCs Differs from the Inherited Virus.
Previous reports indicate that HHV-6 may be reactivated from its inherited form (15,36).
In this study, five open reading frames (U11, U18, U20, U47, and U91) were cloned and
sequenced using genomic DNA isolated from whole blood obtained from Family
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1/Sibling 2 as template. To determine if the inherited virus was induced by
TPA/hydrocortisone treatment, we compared the reactivated virion DNA sequence and
the genomic DNA sequences. In all cases, the reactivated sequences differed from the
inherited sequences (Table 13). Of the genes studied, the immunodominant U11
tegument protein and the U91 membrane protein had the greatest difference when
compared to the inherited virus. Variation in nucleotide sequence indicates that this
individual presenting with CFS-like symptoms harbored an HHV-6 strain distinct from
the virus which was inherited by germline transmission.
Table 12: Most Divergent Open Reading Frames When Comparing the Reactivated
Virus to HHV-6A GS and HHV-6A U1102
Nucleotide
Identity

Gene
ID
U11
U17
U18
U19
U20
U24
u31
u47
U46
U62
U76
U79
U90
U91

Putative Function
Tegument protein pp150
Tegument protein vICA
Envelope glycoprotein
UL37
Protein UL38-anti-apoptotic
Membrane protein U20
Protein U24
Large tegument protein
Envelope glycoprotein O
Envelope glycoprotein N
Protein UL91
Capsid portal protein
Protein UL112
Regulatory protein IE1
Membrane protein UL124

Amino Acid
Identity

GS

U1102

GS

U1102

99.7
100.0

97.8
99.0

99.3
100.0

95.4
98.5

99.6
99.6
99.9
100.0
99.97
99.95
100.0
100.0
100.0
100.0
99.8
100.0

97.6
98.1
98.8
97.7
99.49
98.44
98.4
98.5
99.7
96.4
97.7
97.2

99.1
99.0
97.0
100.0
94.85
93.8
100.0
100.0
100.0
100.0
99.6
100.0

95.2
96.7
94.4
96.6
97.68
97.25
96.4
96.5
96.9
92.2
95.3
93.5
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Figure 12: Nucleotide Alignment of U18 Envelope Glycoprotein Sequences. PCRamplified HHV-6 glycoprotein U18 was TA cloned and sequenced. Obtained nucleotide
sequences were translated using Expasy Translate and aligned using Clustal Omega.

AIM 3: Test the Efficacy of Antiviral Treatment in Suppression of HHV-6
Reactivation/Replication
Prevalence of CIHHV-6 in Cohort of Patients with Neurological Symptoms
To reveal the prevalence of CIHHV-6 in 337 US patients suffering from a wide
range of CFS-related neurological symptoms, including long term fatigue, peripheral
blood samples were tested by quantitative PCR by Viracor-IBT laboratories, Inc. Seven
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patients had higher than 0.5 million HHV-6 copies per ml of blood. A two-tailed Fisher
exact test was used to determine the significance of CIHHV-6 prevalence among these
patients. The CIHHV-6 rate among this cohort of US adult patients suffering from CFS
patients suffering from neurological symptoms was 2.1% (7/337). This is significantly
greater (p=.03) than the expected value of 0.8% reported in the general US population
(34,64).
CFS Patients with CIHHV-6 Express Viral mRNAs, and Long Term Antiviral
Treatment Abrogates Viral mRNA Production
The four patients enrolled in this study harbored over 0.5 million copies of HHV-6
DNA copy numbers per ml of peripheral blood. Patients presented with a variety of
neurological symptoms including but not limited to headache, blurred vision, and
memory impairment, as well as other symptoms such as generalized pain and long term
fatigue.
To determine if the symptoms correlated with replicating HHV-6, nested RT-PCR
was employed to detect the late envelope glycoprotein U100 mRNA in whole blood
samples from patients with CIHHV-6 (93). Initial RT-PCR assays were performed on
blood samples isolated from symptomatic patients prior to the administration of antiviral
medications, and follow-up samples were taken during or after treatment. For each RTPCR reaction, 5ng of total RNA isolated from peripheral blood was used. In all cases,
U100 mRNA was detected in blood samples, in the absence of antiviral treatment
(Figure 14, 15, 16). On the other hand, ten control single donor samples obtained from
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U20 Membrane Protein
AA Length

% Identity

Reactivated

234

HHV-6A GS

422

97.01

HHV-6A U1102

422

94.44

Figure 13: Nucleotide Alignment of U20 Membrane Protein Sequences. PCRamplified HHV-6 glycoprotein U20 was TA cloned and sequenced. Obtained nucleotide
sequences were translated using Expasy Translate and aligned using Clustal Omega.
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Table 13: Nucleotide Comparison: Inherited vs. Reactivated Virus
Gene ID

Mismatches/Total nucleotides

% Difference

U11

87/2616

3.1

U18

16/882

1.81

U20

16/1268

1.34

U47

31/1858

1.46

U91

21/564

2.84

the local blood bank were negative for U100 mRNA (data not shown). In the absence of
reverse transcriptase, PCR products were not detected. Long term (≥six weeks)
administration of foscarnet (patient 4) or valganciclovir (patient 3) resulted in the
abrogation of U100 mRNA expression (Figure 15 and 16), while short term (three
weeks) administration of valganciclovir was not sufficient to eliminate viral gene
expression in two unrelated patients (patients 1 and 2) (Figure 14). Five weeks after the
cessation of intravenous foscarnet treatment (patient 4), U100 mRNA was detected in
the whole blood of patient 4. In all cases, resolution of symptoms was concurrent with
the reduction of mRNA expression. This suggested that U100 mRNA detection is a
reliable method of detecting HHV-6 persistence. However, treatment efficacy was
variable and appears to be dependent on the length of treatment, with treatment length
of greater than or equal to six weeks being optimal for valganciclovir and foscarnet.
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The Late U100 viral mRNA may Originate from an Exogenous HHV-6 Strain
Amplified U100 cDNA was sequenced to confirm that the RT-PCR products were
derived from mature mRNA that lacks introns rather than the inherited viral DNA.
Sequencing was also performed to determine if the detected mRNA originated from the

Figure 14: Amplification of Envelope Glycoprotein U100 mRNA after Three Week
Valganciclovir Treatment. Nested reverse transcriptase PCR was used to amplify
HHV-6 glycoprotein U100 mRNA from whole blood. Total RNA was converted to cDNA
and two rounds of PCR were performed. Second round PCR products were separated
by agarose gel electrophoresis, stained with ethidium bromide, and visualized using UV
light. Top U100 RT-PCR (Lane 1: 100bp Ladder, Lane 2: Patient 1, before treatment,
Lane 3: Patient 1, 3 weeks post treatment, Lane 4: Patient 2, before , Lane 5: Patient 2,
3 weeks post treatment, Lane 6: negative control (Molt3 T-cells). Lane 7: positive
control Molt3 T-cells infected with HHV-6A U1102. Bottom: Beta-actin RT-PCR)
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Figure 15: Amplification of Envelope Glycoprotein U100 mRNA after Long Term
Valganciclovir Treatment. Nested reverse transcriptase PCR was used to amplify
HHV-6 glycoprotein U100 mRNA from whole blood. Total RNA was converted to cDNA
and two rounds of PCR were performed. Second round PCR products were separated
by agarose gel electrophoresis, stained with ethidium bromide, and visualized using UV
light. Top U100 RT-PCR (Lane 1: 100bp Ladder, Lane2: Patient 3, before treatment, Lane
3: Patient 3, 6 weeks post treatment, Lane 4: Patient 3, 12 weeks post treatment , Lane
5: negative control (Molt3 T-cells), Lane 6: positive control (Molt3 T-cells infected with
HHV-6A U1102). Bottom: Beta-actin RT-PCR.

56

Figure 16: Amplification of Envelope Glycoprotein U100 mRNA after Long Term
Foscarnet Treatment. Nested reverse transcriptase PCR was used to amplify HHV-6
glycoprotein U100 mRNA from whole blood. Total RNA was converted to cDNA and two
rounds of PCR were performed. Second round PCR products were separated by
agarose gel electrophoresis, stained with ethidium bromide, and visualized using UV
light. Top U100 RT-PCR (Lane 1: 1kb Ladder, Lane2: Patient 4, before treatment, Lane 3:
Patient 4, 6 weeks post treatment, Lane 4: Patient 4, 5 weeks after cessation of
treatment, Lane 5: negative control (Molt3 T-cells), Lane 6: positive control (Molt3 Tcells infected with HHV-6A U1102). Bottom: Beta-actin RT-PCR.

inherited virus, or from an exogenous virus. The U100 gene of the inherited viral
genome was also amplified and both cDNA and inherited HHV-6 DNA sequences of
U100 were cloned and sequenced. For sequences from the inherited viral DNA
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fragments, introns were removed using previously accepted splice sites prior to
alignment using ClustalW2. Isolated cDNA sequences were also compared to the U100
sequences for HHV-6A U1102 and GS, or HHV-6B Z29. All patient cDNA sequences
were more similar to HHV-6A U1102 than HHV-6A GS and differed from HHV-6A
U1102 by only a CG inversion at bases 193/194 (Figure 17). On the other hand, the
inherited genomic sequences were more similar to HHV-6A GS. The inherited HHV-6A
sequences were greater than 99% identical to each other for three patients, as were all
the reactivated viral sequences.
The cDNA and inherited genomic sequences differed from each other in all
cases. U100 cDNA shared only an average of 96.3% nucleotide sequence identity with
the inherited HHV-6A viral genome. U100 cDNA from patient 1 was more similar to
HHV-6A U1102, while the inherited HHV-6 DNA sequence was 98% identical to HHV6B Z29 (Figure 17). In addition, the U100 mRNA sequence and inherited viral DNA
sequences shared only a 90% nucleotide sequence identity (Figure 18). Differences in
the genomic DNA and cDNA sequences demonstrate that these symptomatic patients
with inherited HHV-6 harbor more than one HHV-6 virus, and the U100 mRNA detected
by RT-PCR originates from an exogenous virus.
Inherited HHV-6 Viral Genome Sequences are Heterogeneous
Our results clearly indicated that the reactivated virus from these patient samples
did not emanate from the major inherited virus. In all cases the reactivated viruses were
more similar to HHV-6A U1102 than HHV-6A GS. Additionally, there was a high level of
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similarity between the U100 DNA sequences of the inherited viruses. To compare the
genome of the inherited HHV-6 viruses to the HHV-6A GS virus, we performed
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Figure 17. Nucleotide Alignment of cDNA and Genomic Sequences Compared to
HHV-6 Laboratory Strains. PCR amplified HHV-6 glycoprotein cDNA or corresponding
genomic DNA fragments were TA cloned and sequenced. Obtained sequences were
aligned using the Mauve algorithm and visualized in JalView in the ViPr database.
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Figure 18. Nucleotide Alignment of cDNA and Genomic Sequences for Patient 1.
PCR amplified HHV-6 glycoprotein cDNA or corresponding genomic DNA fragments
were TA cloned and sequenced. Obtained sequences were aligned using Clustal
Omega.

restriction fragment length analysis on DNA from four patient’s PBMCs or GS virion
DNA.
Briefly, DNA was subjected to restriction enzyme digestion using SacI; fragments
were separated by electrophoresis, blotted onto nitrocellulose and probed with a
radiolabeled HHV-6A U1102 BAC clone (Figure 19). Despite similarities among the
inherited HHV-6 sequences, Southern blot hybridization showed distinct banding
patterns for each inherited virus and a significantly diverged banding pattern from HHV-
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6A GS, indicating that all inherited viruses evaluated in this experiment markedly differ
from HHV-6A GS and are also uniquely distinct from each other.

Figure 19: Restriction Fragment Analysis of Inherited HHV-6 Viruses. Cellular DNA
from patient PBMCs or virion DNA from HHV-6 GS was digested using SacI. Fragments
were separated by electrophoresis, blotted onto nitrocellulose and probed with a
radiolabeled HHV-6A U1102 BAC clone. Lane 1: HHV-6A GS virion DNA, Lane 2:
patient 5, Lane 3: patient 3, Lane 4: patient 4, Lane 5: patient 6; patient 6 is from Family
1, Sibling 2 (15,18).
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DISCUSSION

Note to Reader
Portions of this chapter have been previously published in Journal of Medical
Virology, 2013, 85(11): 1940-1946 and has been reproduced with permission from
Wiley Periodicals, Inc.
Latency of HHV-6
In the first part of this study, single cell HEK293/HHV-6A clones were established
in vitro. Interestingly, HHV-6A infected HEK293 cells could be segregated into three
groups: (1) cells that stopped replicating after HHV-6 infection, (2) cells that continued
replicating after HHV-6 infection that were initially PCR positive for HHV-6A and later
lost the viral genome and (3) cells that were infected with HHV-6A and maintained the
viral genome in the telomeres, as evident by FISH analysis. These results were
unexpected and indicate areas that need to be addressed in the future.
HEK293 cells are positive for telomerase, a reverse transcriptase that extends
the 3’ ends of chromosomes (126); however, replicative senescence followed HHV-6
infection in some HEK293 infected single cell clones. This suggests that HHV-6
integration may abrogate telomerase activity in specific chromosomes. Alternatively,
HHV-6 integration may lead to telomere instability and lead to senescence if integration
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of the viral genome occurs in a region of the human genome essential for cell division,
or for other unknown reasons.
Subtelomeres are transcribed by RNA polymerase II into non-coding RNA known
as TERRA (telomeric repeat-containing RNA) (127). TERRA, exclusively located in the
nucleus, plays a role in heterochromatin formation, but also induces telomere (128,129).
TERRA molecules are similar in sequence to telomeric DNA and competes with
telomeres for telomerase binding (128). Furthermore, TERRA induces telomere
shortening by stimulating the expression of exonuclease 1 expression at chromosome
ends (128,129). Insertion and transcription of the entire HHV-6 genome into the
subtelomere may indirectly stimulate TERRA transcription and lead to telomere
shortening. This effect, however, may vary depending on the site of integration.
Unfortunately, due to large amounts of chromosomal rearrangements in HEK293 cell
lines, FISH analysis was not able to identify the specific site of integration for
HEK293/HHV-6A single cell clones. The effect of HHV-6 integration on TERRA
transcription and telomerase activity in vivo in infected patients has not been
investigated, but is an interesting and important subject which should be explored.
Loss of the viral genome after subsequent growth in cell culture was also noted
in seven of the ten originally established HEK293/HHV-6A single cell clones. We
hypothesize that if the viral genome integrates close to the physical end of the
chromosome, rapid loss of HHV-6 genome may occur due to end replication problems.
Failure to maintain the viral genomes close to the end of the chromosome may also be
related to the loss of telomerase function proposed previously, with the affected cell
eventually losing the viral genome.
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The third outcome, maintenance of the viral genome over time, shows that
HEK293 cells can be used as an in vitro model for HHV-6 infection, latency, and
reactivation. There have been no in vitro HHV-6 models established thus far. This
model will prove useful for testing of recombinant/mutant of HHV-6 strains in vitro, and
the effect of individual viral genes on the viral integration and reactivation.
Reactivation of HHV-6
An additional phenotypic difference seen with HEK293/HHV-6A clones was the
inducibility with epigenetic modifiers TSA, sodium butyrate, carbamazepine, or valproic
acid. Of the three clones tested, only one was inducible, and of the epigenetic modifiers
inhibitors only TSA was capable of inducing viral reactivation from its integrated form.
All of the epigenetic modifiers tested are histone deacetylases (HDACS). Histone
deacetylation results in compaction of heterochromatin and the repression of
transcription; thus, inhibition of HDACs typically leads to an increased gene expression.
The most probable explanation for differences observed in the efficacy of the HDAC
inhibitors is specificity. HDACs fall into five classes. Four of the classes include the
classical or zinc-dependent HDACS (Table 14). The class III HDACs are made up by
the sirtuin family of proteins. None of the HDAC inhibitors tested in this study were
active against class III HDACs. However, TSA inhibits all zinc-dependent histone
deacetylases (class I, IIa, IIb, and IV); while the other HDAC inhibitors tested are more
specific (130,131). Valproic acid sodium butyrate acid specifically inhibits class I and IIa.
Carbamazepine has some selectivity against class I, IIa, and IIb, but to date has only
been shown to be active against three HDACS: HDAC3, 6, and 7 (132,133).
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When HEK293/HHV-6A single cell clones were treated with TSA, reactivation
resulted in concatemer formation by PCR amplification and Southern blot hybridization
(Figure 19). Interestingly, during reactivation the length of the direct repeat was variable
as indicated by the presence of different sized bands when the Southern blot was
probed with a radiolabeled DR probe. The DR regions of the viral genome are variable
and ranges in size from 8kbp to 13kbp, with up to 1kbp of this being comprised of
Table 14: Zinc-dependent Histone Deacetylases (130,131).
Class

HDAC

Localization

Class I

HDAC1

Nucleus

HDAC2

Nucleus

HDAC3

Nucleus

HDAC8

Nucleus

HDAC4

Nucleus/cytosol

HDAC5

Nucleus/cytosol

HDAC7

Nucleus/cytosol

HDAC9

Nucleus/cytosol

HDAC6

Nucleus/cytosol

HDAC10

Nucleus/cytosol

HDAC11

Nucleus/cytosol

Class IIa

Class IIb

Class IV

telomere repeats. Presumably, homologous recombination may occur at any location
within the telomere-like repeats; thus, this is one probable explanation for the variation
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in DR length seen after circularization. It is also possible that there deletions occur in
the DR region during viral reactivation, as the smallest size DR detected by Southern
Blot is about half the size of the HHV-6 DR length previously recorded in the literature
(5,6,9). Large deletions of up to 5.4kb at internal regions in the internal regions of the
DRs have been observed during passage of HHV-6 viruses in T-cell in vitro (134),
resulting in DR lengths similar to those seen in this study. The exact regions of deletions
have not been elucidated in this study, but could be accomplished by cloning and
sequencing of the PCR amplified products.
Proposed Mechanism of HHV-6 Latency & Reactivation
It has been well established that HHV-6 establishes latency in vitro by integration
into the telomeres of host chromosomes. In order for homologous recombination to
occur, DNA strands must be cleaved. The most probable candidate for this activity is
theHHV-6 protein U94, which is homologous to the Rep78/68 protein of the adenoassociated virus type 2(AAV-2). AAV-2 and HHV-6 are similar in that both specifically
integrates into the host chromosomes, however, AAV-2 integration has only been found
to occur in chromosome 17 and integration occurs in a region outside of the telomere.
The Rep78/68 is important for AAV-2 integration and possesses DNA binding,
endonuclease, and helicase activity. The HHV-6 protein U94 has confirmed DNA
binding activity and complements the activity of Rep deficient viruses and likely
performs a similar function((135,136). However, to date there are no reports of
endonuclease and helicase activity for this protein.
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The model proposed here for integration and latency begins with cleavage of the
viral telomere repeats by protein U94. Following cleavage, strand exchange and
homologous recombination would occur, resulting in the integration of the entire viral
genome into the subtelomere of the host chromosome. In this study, TSA was shown to
induce the reactivation of latent HHV-6 from its integrated form; we propose that TSA
treatment leads to the expression of a viral gene, which we propose is protein U94,
which aids in excising the viral genome from the subtelomere and facilitates
circularization of the viral genome. Replication of the circular intermediate results in the
formation of concatemers of the viral genome (Figure 20).
Nucleotide and Amino Acid Variation of HHV-6
An HHV-6A virus isolated from Family 1/Sibling and completely sequenced was
compared at the nucleotide and amino acid level to both HHV-6A GS and U1102, and
our results indicate that the virus is distinct from either of the HHV-6A strains which
were previously sequenced. Analysis of the whole genome sequence results clearly
indicate that some regions of the reactivated virus are highly conserved when compared
to the two fully sequenced HHV-6A variants. Interestingly, the reactivated virus from
Family 1/Sibling 2 was >99% identical to the HHV-6A GS strain. We suspect that the
two viruses may be similar because of the geographic region of isolation. Both the
reactivated virus and the GS strain were isolated in North America, while the U1102
isolate was obtained from an individual in Uganda. The close sequence similarity
between the GS virus and the Family 1/Sibling 2 virus, which were both isolated in
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North America, and their divergence from the U1102 strain isolated in Uganda suggests
that HHV-6 viruses may be further segregated into geographical subtypes.
The current study indicates that intrastrain variation may be as high as 3% at the
nucleotide level and 8% at the amino acid level, and this is higher than previously
recognized variation. These differences may pose difficulties when designing PCR
primers and may lead to failure to identify individuals with HHV-6 in routine clinical
assays. The divergence seen between the core gene blocks and towards the right end
of the genome are not surprising, as these regions of the genome seem to be hotspot
for variation (5,6). These regions are most divergent when comparing HHV-6A strains
and HHV-6B viruses. Nevertheless, high levels of conservation at some open reading
may indicate biological significance and these genes may prove useful in development
of HHV-6 PCR assays for detection. Three of the most highly conserved genes were not
located in the herpesvirus core gene blocks and were not unique to roseoloviruses
(Table 11): U47A, U60, and U63. No work has been done to characterize the function of
either of these genes, and future studies should address this issue. Open reading
frame U47A is located immediately downstream of the hypervariable U47 gene region,
and is presumed to encode an envelope glycoprotein. However, no work has been done
to further characterize this gene. The U60 spliced late gene which encodes a DNA
packaging terminase, is the most conserved gene when comparing HHV-6A and HHV6B viruses, although it is sometimes designated U66 in the B variants (5,6). Finally, U63
is an uncharacterized protein, but relationship to HCMV UL92 has been proposed. CMV
UL92 is a betaherpesvirus-specific gene that is essential for CMV replication in
fibroblasts; however, it also has not been fully characterized (137).
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Figure 20: Proposed Mechanism for HHV-6 Integration and Reactivation
Homologous recombination between the host telomeres and viral telomeres are
facilitated by the viral protein U94, which probably cleaves the viral telomeres to allow
strand exchange and recombination. Reactivation, induced by TSA, results in
expression of viral genes, such as U94, that function to allow recombination of the viral
telomere repeats and result in the circularization of the viral genome. The circularized
viral genome is replicated, and results in the formation of concatemers.
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The predicted amino acid sequences of two proteins, U18 and U20, located
between the betaherpesvirus core gene block and the first conserved herpesvirus core
gene block, were shorter than the amino acid sequences for HHV-6A GS and U1102.
The U18 envelope glycoprotein was 66 amino acids shorter than the amino acid for
HHV-6A GS and HHV-6A U1102, and the U20 protein was 188 amino acids shorter
than the laboratory strains, GS and U1102. Both of these proteins are preferentially
expressed in HHV-6B chronically infected T-cell lines. However, the function of neither
of these proteins in HHV-6A viruses has been fully characterized (138). Recent reports
indicate that for HHV-6B viruses, U20 is involved in inhibition of tumor necrosis factor
receptor induced apoptosis in infected cells (139). However, the function of U20
encoded by HHV-6A, which bears only a 90% amino acid identity to HHV-6B U20, has
not been investigated. The HHV-6A and HHV-6B U18, U19, U20 genes (previously
named EJFL6, EJFL4, and EJFL3) differ in temporal regulation and splicing patterns.
Both U18 or U20 may be expressed as full length proteins or a splice product of the
three open reading frames may be produced (138,140). For HHV-6A, the U19 is
excluded by splicing and produces a transcript shorter than the HHV-6B transcript
(526bp vs 1.9kbp) expressed during the first 8 hours of infection, while the HHV-6B
splice product is expressed up to 24 hours post infection.
Inherited Herpesvirus Syndrome (IHS)
Although inheritance of HHV-6 occurs infrequently, by using previously reported
prevalence estimates approximately 2.5 million people in the United States have
inherited the virus. This is a conservative estimate, as wide scale studies assessing
prevalence have not been performed, and increased prevalence has been noted in
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hospitalized individuals and individuals displaying neurological dysfunction (40,42–
49,86,92). The patients in this study represent a unique population of individuals with
chronic fatigue syndrome that have inherited HHV-6. Approximately 1.25 million
individuals in the United States suffer from chronic fatigue syndrome; if the CIHHV-6
prevalence reported in this study holds true (over 2%), this unique population would be
made up of more than 25,000 people. The increased CIHHV-6 prevalence in this
population suggests a role of HHV-6 in CFS pathology. In support of this hypothesis, in
this study we documented late viral mRNA production in all four unrelated patients with
CIHHV-6 and chronic fatigue syndrome-like neurological symptoms. In contrast, viral
mRNA was reported in only 8% of asymptomatic CIHHV-6 (34).
Surprisingly, the sequence of the late mRNAs markedly differed from the
inherited viral genome sequences in CIHHV-6 positive patients with CFS-like
neurological symptoms. The presence of an exogenous persistently replicating HHV-6
virus suggests that patients with CIHHV-6 exhibit immune tolerance or
immunosuppression. It has been shown that the humoral response to inherited HHV-6
differs from primary infection. A study by Tanaka-Taya et al. supports the notion of
immune tolerance in CIHHV-6 patients (38). There, only 14% had detectable antibodies
directed at glycoprotein B, the major neutralizing epitope, compared to 60% detection in
healthy adult controls(38). Reduced gB titers suggest that individuals with CIHHV-6 may
have a reduced ability to fight a secondary HHV-6 infection. Additionally, several studies
of cellular response to HHV-6 indicate that there is a low frequency of circulating HHV-6
responsive T-cells (105–107). Currently it is unclear if this phenomenon holds true for
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individuals harboring CIHHV-6, but low frequency of responding T-cells may contribute
to repeated HHV-6 infections.
To date, there have been no studies on the rate of superinfection in patients with
inherited HHV-6. This study suggests that, in symptomatic CIHHV-6 patients, infection
with an exogenous HHV-6 virus may be a frequent occurrence. Additionally, we propose
that superinfection is the differentiating factor between symptomatic and asymptomatic
individuals with CIHHV-6; however, this was not directly investigated in this study.
Taken together, we propose that some CIHHV-6 individuals acquire and are persistently
infected with exogenous HHV-6 strains that lead to a wide range of neurological
symptoms. We propose to name this condition inherited herpesvirus 6 syndrome or IHS.
The virus isolated and sequenced from Family 1/Sibling 2 differed from the inherited
virus at five open reading frames analyzed and this individual also suffered from CFSlike neurological symptoms; according to the above criteria, this individual also suffers
from IHS (Table 13).
Results indicate that patient response to antiviral therapy using oral
valganciclovir or intravenous foscarnet was largely dependent on treatment length. A
three week treatment with valganciclovir was ineffective in preventing virus reactivation,
as indicated by the recurrent expression of U100 mRNA. We recently documented the
long-term benefit of antiviral drug therapy of two patients with IHS, one of which was
Family 1/Sibling 2 (83). Both of these patients have suffered debilitating neurological
symptoms but antiviral therapy resulted in marked and long-lasting improvement also
documented by quantitative EEG (83). Years after cessation of antiviral therapy, we
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were unable to detect detectable U100 mRNA in their PBMCs and these individuals are
also free of neurological symptoms.

Reactivation of Inherited HHV-6
There have been previous reports of reactivation of integrated HHV-6. Arbuckle
et al. 2010 demonstrated in vitro reactivation of integrated HHV-6 by chemical inducers,
such as TPA and trichostatin. More recently, Gravel et al. reported the transmission of a
CIHHV-6 strain transplacentally from mother to child, in the absence of inheritance
(15,36). In the first, sequencing of the direct repeat and the U94 gene revealed that the
reactivated and inherited viruses were identical (15). In the latter study, evidence for this
transmission comes from nucleotide sequence comparison of a portion of the U39
envelope glycoprotein B, and the presence of unique polymorphisms in the DNA
sequences of both the mother and infant (36). Here, we employed a similar strategy by
sequencing genomic DNA and cDNA isolated from the same patient. However, our
results indicate that the detected mRNA arose from only an exogenous HHV-6 virus in
all the patient samples evaluated, rather than the inherited viruses. We did not see
evidence of reactivation of the CIHHV-6 virus. However, it is possible that this occurs as
well and that the copy number is too low to be detected. Contradictions between this
study and previously mentioned studies suggest that the ability of CIHHV-6 viruses to
reactivate is a complex process, and may vary from one individual to another.
Immunological status may play a role in the ability of individuals to be infected with
exogenous HHV-6 or for the reactivation of the latent inherited virus. No studies have
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conclusively shown the lack of neutralizing antibodies in CIHHV-6 individuals, and
antibodies directed against the HHV-6 IE-A gene were detected at a higher rate in
CIHHV-6 individuals (38). This indicates that some CIHHV-6 individuals are capable of
mounting an immune response to HHV-6; these individuals may be less susceptible to
continuous reactivation of the virus or reinfection by exogenous strains of the virus. The
differences in observed immune responses may be due to the ability of the immune
system of some individuals to override immune tolerance. Alternatively, the degree of
differences between the sequence of dominant antigen epitopes of the inherited viral
genes and contemporary virus isolates may also impact immune response.
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FUTURE DIRECTIONS
The current study demonstrated reactivation of integrated HHV-6 in in vitro
models and the propensity for infection with exogenous HHV-6 strains in individuals with
an inherited form of the virus. Although HHV-6 and its inheritance have been recognized
by a number of studies, there are limited studies focusing on CIHHV-6 and the
characterization of HHV-6 strains. Below are suggestions of future studies which are
imperative for the understanding of HHV-6 latency and inheritance.
Prevalence of CIHHV-6 in Neurological Disorders
Large multi-site studies should focus on determining the prevalence of CIHHV-6
in chronic fatigue syndrome and other neurological disorders. In this study, there is
limited evidence that the rate of HHV-6 inheritance may be greater than the proposed
0.8% in the United States population. Other studies have also demonstrated increased
prevalence of inheritance in individuals hospitalized for a variety of conditions (40,42–
49). Many hospitals and research institutions have repositories of biological specimens
and testing for CIHHV-6 is simple and cost efficient.
Detection of CIHHV-6 can accomplished by quantitative real time PCR analysis
performed on whole blood, hair follicle, and other biological specimens. Amplification
of the U67 open reading frame has previously been used as a means of determining
CIHHV-6 prevalence (66) and will be used here. A result of greater than 106 viral copies
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per ml would indicate inheritance of the virus. Prevalence will be calculated by dividing
the number of inherited cases by the total number of samples tested. Statistical
significance will be determined using the Fisher’s Exact test, as described previously
(66).
Cellular and Humoral Responses to HHV-6 in CIHHV-6 Individuals
Future studies should evaluate cellular and humoral response to HHV-6 in
individuals with an inherited form of the virus. More recently, several research groups
have focused on the cellular and humoral response to HHV-6 (105,107,141). However,
none of these studies have evaluated these responses in individuals with an inherited
form of HHV-6. This is an important area of research which needs to be addressed in
the near future, considering the implications of the current study. One of the most
variable genes noted in sequencing study was U11, an immunodominant tegument
protein (Table 13). A recently published article looked at the antibody response to this
protein in individuals suffering from CFS and found no differences in antibody response
when compared to healthy controls (88). However, one limitation of this study is that it
failed to look at individuals with an inherited form of the virus.
PBMCs will be isolated from CIHHV-6 or non-CIHHV-6 individuals by density
gradient centrifugation (Lymphoprep) and maintained in RPMI-1640 medium with 10%
FBS and 50µg/ml gentamicin. For T-cell expansion cells will be maintained in culture
medium containing phytohaemagglutinin (20μg/million cells) and 50U/ml interleukin-2. A
Low HHV-6 specific T-cell frequency has previously been reported (105–107), therefore,
ex vivo expansion with HHV-6 antigen may be necessary prior to functional assays.
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HHV-6-specific T-cell response be assessed by interferon gamma enzyme-linked
immunosorbent spot assay, and the functional characteristics of HHV-6 specific CD4+
and CD8+ T-cells will be determined by intracellular cytokine assays.
For evaluating humoral response, we propose measuring serum titer of antiHHV6 neutralizing antibodies (gB) and anti-U11 antibodies by ELISA. Statistical
significance of differences in responses between CIHHV-6 and non-CIHHV-6 individuals
will be assessed using the student’s p-test.
Functional Characterization of HHV-6 Encoded Proteins
Considering that HHV-6A and HHV-6B are important human pathogens, there
have been limited studies characterizing the function of HHV-6 encoded proteins. The
present study highlighted a number of open reading frames which are either well
conserved or highly variable from one strain to another. Characterization of genes which
fall into either of these categories will allow researchers to understand the molecular
basis for interstrain and intrastrain differences observed for HHV-6 strains.
Our group previously used an HHV-6A BAC vector to created a chloramphenicolselectable green fluorescent-protein (GFP) expressing HHV-6A virus (15); this vector
allows for manipulation of the viral genome in an E. coli system. First, PCR will be used
for generating deletion cassettes which contain the flanking region of individual open
reading frames, the kanamycin gene, and loxP (locus of X-over P1) sites. The purified
deletion cassette will then be transformed into E.coli cells containing the HHV-6A BAC
vector and mutants will be selected for by LB agar plates containing chloramphenicol
and kanamycin. Deletion of selected open reading frames will be confirmed by
78

restriction enzyme digestion and southern blot analysis. To generate revertant mutants
the recombinant BAC vector can be transformed into E. coli cells expressing the Cre
(Cyclization recombinase) site-specific recombinase. Recombination will occur, result in
the deletion of the kanamycin cassette and result in an intact copy of the viral gene.
After generation of the knockout BAC vector, virus reconstitution will be
accomplished by transfecting the BAC vector into HEK293 cells and growing the cells
until cytopathic effect is visible. The recombinant or revertant wild-type virus will then be
isolated by several freeze thaw cycles and harvesting of supernatant after high speed
centrifugation to remove cellular debris.
Once generated, the knockout genes can be assessed for their ability to
establish latency and be reactivated from latency. Establishment of latency can easily
be tracked flow cytometry or fluorescent microscopy when working with a GFP
expressing mutant virus. In our experience cells infected with an HHV-6 GFP
expressing viruses fluoresce brightly during early times of infection and fluorescence
intensity lowers as latency is established. Fluorescence should again increase after
addition of TSA, and induction of viral replication.
Characterization of Inherited Herpesvirus-6 Genomes
There is little known about the genetic variability of inherited HHV-6 viruses, and
future studies should focus on characterizing inherited HHV-6 viruses in detail.
Restriction fragment analysis and sequencing number of viral genes, suggests that
inherited HHV-6 viruses are divergent when compared to each other and previously
characterized HHV-6 viruses. Full genome sequencing of the inherited genome may
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reveal critical antigen epitope variability in addition to mutations with the potential to
cause viral replication defects. Sequence variation may also affect the ability of inherited
viruses to reactivate or determine whether inherited viral genome expression occurs.
Furthermore, it is also possible that some HHV-6 viruses that have entered the germline
viruses differ in tropism than other viruses and can more efficiently infect gonad or pregonad cells. These differences may be a contributing factor to why CIHHV-6 is present
in only a small fraction of the population, although HHV-6 viruses are ubiquitous.
To characterize inherited HHV-6 sequences, whole genome sequencing can be
performed on DNA isolated from whole blood of CIHHV-6 positive patients. We propose
the use of 454 sequencing methodology to accomplish whole genome sequencing of
the inherited viral genome. We expect that sequencing will be partially incomplete in the
portions of the viral genome containing repetitive sequences and that PCR amplification
and cloning will be necessary to complete the viral genome. Assembly of the sequenced
viral genome will be performed using HHV-6A U1102 or HHV-6B Z29 as reference
strains. Nucleotide sequences and translated amino acid sequences for individual open
reading frames will be aligned with prototype sequences, and evaluated for potential
truncations and significant differences in coding sequences.
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CC BY, the CC BY-NC and the Attribution-NoDerivatives (CC BY-NC-ND). The CC BYNC-ND is more restrictive than the CC BY-NC as it does not permit adaptations or
modifications without rights holder consent.
Wiley Open Access articles are protected by copyright and are posted to repositories and
websites in accordance with the terms of the applicable Creative Commons license
referenced on the article. At the time of deposit, Wiley Open Access articles include all
changes made during peer review, copyediting, and publishing. Repositories and websites
that host the article are responsible for incorporating any publisher-supplied amendments
or retractions issued subsequently.
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The authors' moral rights must not be compromised. These rights include the right
of "paternity" (also known as "attribution" - the right for the author to be identified
as such) and "integrity" (the right for the author not to have the work altered in such
a way that the author's reputation or integrity may be damaged).
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Where content in the article is identified as belonging to a third party, it is the
obligation of the user to ensure that any reuse complies with the copyright policies
of the owner of that content.
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If article content is copied, downloaded or otherwise reused for research and other
purposes as permitted, a link to the appropriate bibliographic citation (authors,
journal, article title, volume, issue, page numbers, DOI and the link to the definitive
published version on Wiley Online Library) should be maintained. Copyright
notices and disclaimers must not be deleted.
o Creative Commons licenses are copyright licenses and do not confer any
other rights, including but not limited to trademark or patent rights.
Any translations, for which a prior translation agreement with Wiley has not been
agreed, must prominently display the statement: "This is an unofficial translation of
an article that appeared in a Wiley publication. The publisher has not endorsed this
translation."
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Conditions applicable to non-commercial licenses (CC BY-NC and CC BYNC-ND)
For non-commercial and non-promotional purposes individual non-commercial
users may access, download, copy, display and redistribute to colleagues Wiley
Open Access articles. In addition, articles adopting the CC BY-NC may be adapted,
translated, and text- and data-mined subject to the conditions above.
Use by commercial "for-profit" organizations
Use of non-commercial Wiley Open Access articles for commercial, promotional,
or marketing purposes requires further explicit permission from Wiley and will be
subject to a fee. Commercial purposes include:
o

Copying or downloading of articles, or linking to such articles for further
redistribution, sale or licensing;

o

Copying, downloading or posting by a site or service that incorporates
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available for sale or licensing, for a fee (for example, a compilation
produced for marketing purposes, inclusion in a sales pack)
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Use of article content (other than normal quotations with appropriate
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Linking to article content in e-mails redistributed for promotional,
marketing or educational purposes;
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Use for the purposes of monetary reward by means of sale, resale, license,
loan, transfer or other form of commercial exploitation such as marketing
products

o

Print reprints of Wiley Open Access articles can be purchased
from:corporatesales@wiley.com
The modification or adaptation for any purpose of an article referencing the
CC BY-NC-ND License requires consent which can be requested
fromRightsLink@wiley.com .
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THAT YOU HAVE READ AND FULLY UNDERSTAND EACH OF THE
SECTIONS OF AND PROVISIONS SET FORTH IN THIS AGREEMENT
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invoiced within 48 hours of the license date. Payment should be in the form of a check
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Once you receive your invoice for this order, you may pay your invoice by credit card.
Please follow instructions provided at that time.
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Copyright Clearance Center
Dept 001
P.O. Box 843006
Boston, MA 02284-3006
For suggestions or comments regarding this order, contact RightsLink Customer
Support:customercare@copyright.com or +1-877-622-5543 (toll free in the US) or +1978-646-2777.
Gratis licenses (referencing $0 in the Total field) are free. Please retain this printable
license for your reference. No payment is required.
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